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Ras is the most frequently activated oncogene found in human cancer, but its 
mechanisms of action remain only partially understood.  Ras activates multiple signaling 
pathways in order to promote transformation, but can also exhibit a potent ability to 
induce growth arrest and death.  NORE1A (RASSF5) is a direct Ras effector that acts as 
a tumor suppressor promoting senescence and apoptosis.  Its expression is frequently 
lost in human tumors and its mechanism of action remains unclear.  Here I show that 
NORE1A forms a direct, Ras regulated, complex with β-TrCP, the substrate recognition 
component of the SCF-β-TrCP ubiquitin ligase complex.  NORE1A also binds GSK-3β 
resulting in enhanced kinase activity, which is required to phosphorylate SCF-β-TrCP 
substrates before their recognition by the ubiquitin ligase complex.  Thus, by acting as a 
scaffold between β-TrCP and GSK-3β, NORE1A allows for Ras to both qualitatively and 
quantitatively enhance the proteosomal degradation of SCF-β-TrCP targets, such as β-
catenin and TAZ.  However, this control is substrate specific, as IκB, another substrate 




completely novel signaling mechanism for Ras that allows the coordinate regulation of 
the Wnt/β-catenin and Hippo pathways, and potentially multiple other SCF-β-TrCP 
targets.  The mechanism is frequently impaired in tumors by loss of NORE1A expression 
and provides an explanation for the observation that β-TrCP can act as a tumor 
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BACKGROUND AND INTRODUCTION 
 
1.1 - Overview 
 
 Members of the Ras family of small GTP-ase proteins control multiple signaling 
pathways responsible for growth, migration, adhesion, cytoskeletal integrity, survival, 
and differentiation and come in three closely related isoforms, H-Ras, K-Ras, and N-Ras 
[1, 2].  Mutations at codons 12, 13, and 61 render all three Ras isoforms into a 
constitutively active state [1].  These Ras mutations have been shown to induce tumors 
in experimental systems and can be found in approximately 30% of human cancers [3, 
4].  Constitutively activated Ras can stimulate multiple mitogenic signaling pathways, 
including the Raf/MAPK, Ral, and PI3K pathways, resulting in oncogenic transformation 
[5].  While Ras does indeed activate transformative pathways, it can also activate growth 
suppressive pathways promoting apoptosis and Oncogene Induced Senescence (OIS) 
[6-8].  However, the mechanisms by which Ras can promote apoptosis or OIS and how 
these mechanisms are subverted to facilitate tumor development remain poorly 
understood.  Current research has shown that Ras induced cell death appears to be 
mediated by members of the RASSF family of tumor suppressors, which bind activated 
Ras and serve as death effectors [9].  RASSF5, more commonly referred to as 
NORE1A, was the first member of the RASSF family to be characterized and has been 




NORE1A is expressed in most normal tissues, but its expression is lost in many tumors 
due to epigenetic inactivation or calpain-mediated proteolysis [10, 12].  In tumors where 
NORE1A expression was lost, restoration of NORE1A expression diminished the tumor 
phenotype [13].  Moreover, transient expression of NORE1A results in enhanced 
apoptosis and senescence [13, 14].  NORE1A is considered to be a bona fide tumor 
suppressor, as a hereditary genetic defect in NORE1A predisposes the human carriers 
to kidney cancer [15]; however, the biological functions of the Ras/NORE1A interaction 
remain mostly uncharacterized.   
Research and data detailed in this thesis describes the discovery of a novel 
signaling mechanism in which Ras/NORE1A suppresses excessive growth signaling and 
promotes cellular senescence by regulating two growth and survival signaling cascade 
endpoints via poly-ubiquitination and degradation in the 26S proteasome.  Here I will 
show that NORE1A can bind the E3 ubiquitin ligase, β -TrCP.  This interaction is 
regulated by Ras and powerfully enhances the degradation of the terminal executor of 
Wnt signaling, β-catenin.  Furthermore, I show that NORE1A can also bind GSK-3β and 
enhance its phosphorylation of β -catenin.  Considering that substrates, especially β -
catenin, must be phosphorylated by GSK-3β before recognition and ubiquitination by β-
TrCP, this observation provides a potential explanation on why NORE1A can efficiently 
regulate β -catenin protein stability.    After characterizing NORE1A’s role in Wnt 
regulation, I investigated other signaling pathways regulated by both GSK-3β and β -
TrCP that are implicated in cancer.  Regulation of the Hippo and Wnt pathways are 
known to be linked [16, 17], so I decided to also investigate the Hippo signaling pathway, 
specifically focusing on the functional elements of the signaling cascade, YAP and TAZ.  
Initial experiments found that NORE1A suppressed TAZ mediated gene transcription, 
while having little effect on YAP transcriptional activity.  TAZ has a GSK-3β 




possible mechanism allowing for the differential regulation TAZ over YAP exists.  My 
experimental work goes on to show that NORE1A indeed specifically regulates TAZ 
protein levels independently of canonical Hippo signaling by enhancing GSK-3β 
phosphorylation and β -TrCP mediated ubiquitination of TAZ.  I also present evidence 
that NORE1A is a scaffolding element that is integral in stabilizing GSK-3β and β-TrCP 
in a protein complex, providing a mechanistic explanation on how NORE1A enhances 
both phosphorylation and ubiquitination of substrates.  Finally, I show that the loss of 
NORE1A removes a key protection element against excessive growth stimulation and 
resulting in a marked increase in steady state levels of β -catenin and TAZ.  Thus, I 
identify a novel function for NORE1A operating as a Ras regulated scaffold for kinases 
and the β -TrCP ubiquitin ligase complex, resulting in enhanced activity towards key 
oncogenic targets and suppressing excessive growth and survival stimuli.  
 
1.2 - The Discovery of the Ras Oncogene 
 
 Ras genes were initially discovered and characterized as viral genes transduced 
from the genome of rodents [19].  Interestingly, these genes are shown to drive the 
highly oncogenic characteristics of RNA tumor viruses [19].  The study of these viral 
genomes, their conserved eukaryotic cellular complements, along with the 21 kDa (p21) 
proteins produced by these genes helped define the fundamental properties of cellular 
Ras proteins [19].  The first report characterizing mutationally activated and highly 
transforming human Ras genes was made in 1982 [20].  When it was then determined 
that Ras mutations are found in very high frequency in human cancers, including three of 
the “Big Four” most deadly cancers in the United States: Lung, Colon, and Pancreatic 




K-, H-, and N-Ras are the founding members of a superfamily of Ras-related 
small GTPases that now number more than 150 proteins [19].  Characterization of these 
proteins helped establish that small GTPases are operate as multi-functional regulators 
of numerous essential cellular processes [19].  When considering how complex the 
modes of regulation of the Ras superfamily are, it is easy to see how these proteins are 
involved in a spectacularly diverse range of biological processes [21].  Although early 
Ras research was established from a long history of research focused on retroviruses, it 
was the discovery of mutationally activated Ras genes in human cancer that would ignite 
an extensive effort in research focused on understanding Ras protein structure, 
biochemistry, and biology [19]. 
 
Identification of Ras from acutely transforming retroviruses: 
 
The origins of Ras research begins in 1964 when Jennifer Harvey found that a 
sample of purified murine leukemia virus, isolated from a rat suffering from leukemia, 
induced the formation of sarcomas in newborn rodents [22, 23].  The tumorigenic 
properties of these sequences began to be defined in the early to mid 1970’s when Ed 
Scolnick and colleagues determined that the Harvey (Ha-MSV) and Kirsten (Ki-MSV) 
viral strains were actually recombinant viruses with sequences collected from the rat 
genome [23, 24].  These genes were subsequently identified in the human genome and 
determined to be key players in human tumor pathogenesis [20].  In 1973, Ed Scolnick 
and colleagues predicted that the tumorigenic properties of these sarcoma viruses likely 
resulted from the transduction of normal cellular rat sequences into their own genomics 
[25].  Unfortunately, at that time of his prediction, the tools necessary to prove this theory 




In the beginning, the genes we now refer to as Ras were named as variants of 
the src oncogene [19].  They were named Ras (RAt Sarcoma) in part because their 
ability to induce rat sarcomas.  The discovering scientist’s names then became the basis 
for distinguishing each of them from the other: Harvey and Kirsten viral Ras genes, or H-
ras and K-ras, gives rise to the proteins Ha-Ras, or H-Ras, and Ki-Ras or K-Ras [19].  
What would then set the field of Ras research on its end was a report by Varmus, 
Bishop, Vogt, and colleagues that characterized the viral src oncogene as a normal 
chicken gene transduced by the virus into its own genome, thus transforming a normal 
gene into a strong oncogenic element [19, 26].   
Scolnick and colleagues extensively studied Ras throughout the late 1970’s and 
early 1980’s.  This work was then published explaining the eukaryotic origin of the viral 
H-ras and K-ras genes, demonstrating that these genes encode 21 kDa proteins that 
bind GDP and GTP, and described these proteins as being integrated into the plasma 
membrane [27-29].  However, these initial discoveries failed to explain key questions 
about Ras signaling including the framework in which Ras proteins function, what 
proteins affect signals toward Ras, and how Ras proteins pass signals to downstream 
targets in the cell [20].  Early experimental work was slow and complicated because Ras 
is controlled through several different positive and negative regulators and can act upon 
numerous downstream effectors, each with a defined pattern of tissue-specific 
expression and distinct set of intracellular functions.  In the 1980’s, several different of 
assays were used to detect genetic mutations in Ras and were key in discovering the 
roles Ras performs in the pathogenesis of human cancers (Figure 1).  These studies 
determined that mutations in Ras occur in approximately one-third of all human tumors, 
with the highest incidences found in cancers of the pancreas (90%), colon (50%), thyroid 
(50%), lung (30%) and leukemias (30%) [30].  However, for most tumor types, the role of 













Figure 1.  Key Events in the Field of Ras Research - A timeline detailing key 
moments in the discovery and characterization of Ras.  Discoveries in the 1980’s 
explained how Ras is activated and operates as a small GTP-ase protein.  In the 1990’s, 
Ras effectors were beginning to be identified and their effects on the cell characterized.  
From the 2000’s and ongoing today, research continues to work to explain how Ras 
plays a role in tumorigenesis. 
 
Reprinted by permission from Macmillan Publishers Ltd: 
[Nat Rev Mol Cell Biol] (Karnoub, A.E. and R.A. Weinberg, 
Ras oncogenes: split personalities. Nat Rev Mol Cell Biol, 
2008. 9(7): p. 517-31.) Copyright 2008 





mechanisms that regulate Ras along with a better understanding of how Ras acts upon 
secondary messenger systems [30].   
 
Identification of Ras as an Oncogenic Human Gene 
 
Although the high oncogenic capability of acutely transforming retroviruses was 
well known, the realization that human cancers are not inducted by such infections 
quelled the fervor for studying them as a basis of human cancer development [19].  The 
researchers took a new course, establishing a new field of study based on the discovery 
that biologically active eukaryotic DNA could be inserted into mammalian cells by a 
process termed “transfection” [31, 32].  The cornerstone study showing the success of 
this type of laboratory procedure and demonstrating that transfected DNA could induce 
transforming properties was the use of NIH-3T3 mouse fibroblasts as the transfected 
cells [33].  While NIH-3T3 cells are immortalized, they retained some of the normal 
growth characteristics of normal cells including density dependent growth inhibition, a 
high dependence of serum growth factors, failure to grow in soft-agar experiments, or 
form tumors when inoculated into immunocompromised mice [19, 33].  When Weinberg 
and colleagues published a study in 1979 showing that when the NIH-3T3 cells were 
transfected with DNA isolated from chemically transformed rodent fibroblasts, they 
underwent morphologic transformation, the field was once again reinvigorated to 
determine the role of Ras in human cancer [34].  Soon after, other labs published similar 
reports using the same experimental approach described by Weinberg.  In 1981, 
Krontiris and Cooper demonstrated that DNA isolated from the human EJ bladder 
carcinoma line also had transforming capabilities [35], and Weinberg’s group also 




response to these findings, researchers were rejuvenated and focused on the goal of 
identifying and isolating transforming human oncogenes. 
In 1982, the two concurrent fields of Ras study, which were centered on acute 
transforming viral genes and transforming human genes, unexpectedly collided.  Three 
groups concurrently determined that the transforming genes identified in the NIH-3T3 
transfection experiments were actually the same Ras genes previously discovered in the 
Kirsten and Harvey sarcoma viruses [38-40].  Further study focused specifically on these 
sequences of Ras and found that the oncogenic variants contained a very specific set of 
conserved point mutations.  These activating Ras mutations commonly result in amino-
acid replacements at residues 12, 13, and 61 [41].  In 1983, a third member of the 
mammalian family of Ras-related genes, N-ras, was successfully captured and cloned 
from neuroblastoma and leukemia cell lines [42].  Remarkably similar to the H-ras and K-
ras variants, N-ras was also found to contain activating point mutations in human tumors 
[43].   
 
1.3 - Discovering Point Mutations of Ras in Human Cancers 
  
Studies using the NIH-3T3 transfection assay, and later analyses using DNA 
sequencing assays, detected mutationally activated Ras genes in a broad range of 
human tumor cell lines as well as in primary patient tumors [19].  The most conspicuous 
of these discoveries was the remarkably high frequency of Ras mutations were found in 
colon, lung, and pancreatic cases [44-47].  Moreover, in addition to mutations at codon 
12, Ras mutations were later identified at codons 13 and 61 [19].  While there are other 
mutations found in Ras, these occurrences are very rare.  In fact, mutations at codons 
12, 13, and 61 comprise 97-99% of all Ras mutations identified in human tumors and 





The Multi-Hit Model of Oncogenic Transformation 
 
It was not long before the hypothesized role of Ras in the initiation of cellular 
transformation was questioned.  The ability of mutant Ras genes alone to transform NIH-
3T3 cells into invasive and tumorigenic cells gave an initially simple and very misleading 
picture of the genetic basis of cancer [19].  Complicating the issue, another study 
showed that freshly isolated rodent embryo cells would not transform when they 
expressed a mutant Ras oncogene on its own [48].  Soon after, three different 
manuscripts were published noting the ability of H-Ras-12Val to transform primary cells 
that immortalized by the expression of another oncogene, such as myc, SV40 large T 
antigen, or the adenovirus E1A gene [20, 48, 49].  These discoveries fell in line with the 
Knudson hypothesis of a multi-hit model of carcinogenesis and further suggested that 
mutated, constitutively active Ras proteins can only transform cells that have previously 
undergone an oncogenic insult [50, 51].   
The requirement for a cooperative second oncogenic hit was later supported by 
cell culture studies of primary human fibroblasts and epithelial cells where hTERT-
mediated immortalization, inactivation of the p53 and Rb tumor suppressors, and protein 
phosphatase 2A inactivation were all found to help drive Ras-dependent transformation 
[52, 53].  This requirement for complementary oncogenic genetic alterations is consistent 
with the accumulation of genetic mutations in human colon and pancreatic cancers 
combined with the observation that cancer incidences increase with age [19].  
A particularly perplexing issue centers on the preferential mutational activation of 
specific Ras isoforms in different cancers.  There are reports showing that certain types 
of human cancers are specifically associated with mutations in either K-, H-, or N-Ras.  




cancers [54], H-Ras mutations were mostly associated with bladder carcinomas [55], 
and finally N-Ras mutations were described as being primarily localized to lymphoid 
malignancies [56] and melanomas [57].  However, the reasons for the observed tissue 
specificity remain unclear.   
 
1.4 - Mutants of the Ras Oncoprotein and the GTPase Cycle 
 
 Once the molecular basis of Ras activation was shown to be caused by DNA 
mutation resulting a protein structure alteration, research focused on the origins of 
cancer at a molecular level [19].     In 1980, Edward Scolnick and colleagues 
investigated the biochemical features of the H-Ras protein.  They initially described the 
binding of Ras proteins to guanine nucleotides, and determine that Ras may function 
analogously to the heterotrimeric G proteins [20, 58].  Heterotrimeric G-proteins were 
known to possess an intrinsic GTP hydrolysis activity, simply termed “GTP-ase” activity 
[59].  In G-proteins, it is the bound guanine moiety that governs its activity.  When a G-
protein is bound to a GTP molecule, the protein is typically in the active state.  To shuttle 
to an off, or inactive, position, the G-protein will hydrolyze the GTP to a GDP.  
Reactivation of the protein occurs when the GDP is exchanged for the more abundant 
cellular GTP molecules [59].   
 A few years later, additional biochemical evidence showed that Ras proteins 
were indeed GTP-ases (Figure 2).  Several groups demonstrated that mutated Ras 
oncoproteins differ functionally from their normal counterparts because their GTP-ase 
activity was impaired [60-62].  Soon after these discoveries, another group identified an 
oncogenic link between the Gly à Val substitution found at the 12th residue of H-Ras 
and GTP hydrolysis [63].  Moreover, mutations of the 61st residue were also found to be 










Figure 2.  The Ras GTP/GDP Activation Cycle - Diagram of the Ras GTP/GDP 
activation cycle.  When Ras is bound to a GDP moiety, the enzyme is inactive.  GEFs 
(Guanine Exchange Factor) interact with Ras and facilitate the exchange of the bound 
di-phosphate to a tri-phosphate co-factor.  The Ras protein is active in this state.  While 
Ras is able to hydrolyze the GTP to a GDP on its own, the process is quite slow.  
However, GAPs (GTP-ase Activating Protein) greatly enhance this speed of this 
reaction, returning Ras to the inactive state.   
http://physrev.physiology.org/content/physrev/92/1/237/F1.large.jpg	  




Thus, the dysfunction in GTP hydrolysis leads to an excessive activation of the Ras 
protein.  However, increasing degrees of GTP-ase inhibition did not always correlate 
with increasing levels of oncogenic transformation, suggesting that compromised GTP 
hydrolysis is necessary, but not sufficient, for aberrant Ras activation [20, 65].   
 
1.5 - A Closer Look into Ras Activation 
 
 In latter half of 1984, published work concentrating on the functional aspects of 
the regulation of Ras activation started to appear in the scientific literature.  The 
breakthrough study investigating Ras activation observed that an increase in GTP-
binding of cellular H-Ras occurred in response to treatment with epidermal growth factor 
(EGF) [66].  Multiple groups subsequently showed that activation or inhibition of Ras 
proteins by growth factors and cytokines suggested that Ras proteins, in a fashion 
similar to G-proteins, function as signal transducers from membrane-associated 
receptors [67-70].   
 Indeed, studies soon showed that Ras cycles similarly to G-proteins.  Luckily, G-
proteins were much better characterized than Ras, and share important structural and 
sequential homologies, which simplified much of the biochemical and structural research 
on Ras [71, 72].  A more comprehensive picture of Ras protein structure emerged when 
it was crystallized; showing the conformation of the GDP and GTP bound states as well 
as structures of the oncogenic mutants of Ras [73-75].  These studies helped explain the 
molecular features involved in the intrinsic GTP-ase activity of Ras and how mutations 
result in defects in the Ras activation switch. 
The three-dimensional structure of Ras consists of six β -sheets and five α -











Figure 3.  Three Dimensional Structure of the Ras Protein - Model of the 3-
dimensional structure of the Ras protein.  This model highlights the importance of the 
12th, 13th, and 61st residues typically found mutated in constitutively activated Ras.  The 
structure consists of six β -sheets and five α -helices that are linked by a series of ten 
loops.  Mutations in residues 12 and/or 13 prevent GAPs from de-stabilizing and 
hydrolyzing the GTP to a GDP.  The GTP-gamma-phosphate is stabilized by residues 
16, 21, 35, 60, and 61.  Of these, residue 61 coordinates the nucleophilic attack 
necessary for the hydrolysis of GTP to GDP. 
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are found on one lobe of the protein and have functional roles in binding GTP and 
regulating GTP hydrolysis.  The GTP γ -phosphate is stabilized by interactions with 
residues Lys16, Tyr21, Thr35, Gly60, and Gln61 on loops 1,2, and 4 [73].  Of these 
residues, Gln61 appears to coordinate the nucleophilic attack that is necessary for the 
hydrolysis of GTP to GDP by stabilizing the transition state of this reaction [73].  
Accordingly, mutations in Gln61 significantly reduce the intrinsic GTP hydrolysis rate, 
locking Ras in a constitutively active state and making it oncogenic.   
Structural analysis of Ras in the GDP and GTP states revealed two highly 
dynamic regions, termed Switch I and Switch II [73, 74, 76, 77].  Switch I contains 
residues 30-40 and Switch II contains residues 60-76.  Both regions are required for Ras 
to interact with upstream and downstream signaling elements.  Binding of GTP shifts the 
conformation of Switch I by shifting Thr35 inward [76].  This allows Thr35 to interact with 
the GTP-γ-phosphate as well as the required Mg2+ ion cofactor.  In much the same way, 
the bound GTP also changes the orientation of Switch II through interactions with Gly60 
[76].  Functionality of both switches is required for the Ras protein to successfully cycle 
between active and inactive states. 
While Ras contains intrinsic GTP-ase activity, kinetic assays show that it is slow 
and inefficient.  In fact, differences in GTP-ase activity of Ras compared with its 
oncogenic mutants are modest and do not correlate with the degree of transformation 
found in tumors [78].  Thus, there must be other cellular elements facilitating Ras’s GTP 
hydrolysis action.  The discovery of GAPs (GTP-ase Activating Proteins) solved this 
dilemma.  These proteins alter the conformation of Ras to greatly enhance its GTP-ase 
activity, shifting Ras back to an “off” conformation (Figure 2).  The explanation began 
with an investigation of H-Ras in complex with the p120GAP GRD (GAP-Related 
Domain) [79].  Binding of the variable loop of GAP α7 to Switch I of Ras establishes 




interaction with the GAP’s FLR motif (Phe-Leu-Arg), which stabilizes the two switch 
domains provoking a rapid acceleration of GTP hydrolysis [79]. 
Conversely, there are proteins that activate Ras by facilitating the exchange of 
GDP for GTP molecules.  These proteins are called GEFs (Guanine Nucleotide 
Exchange Factors) and they facilitate the exchange of the GDP molecule in favor of a 
GTP molecule (Figure 2).  Because of this interaction, an α -helical hairpin of the GEF 
separates the Switch I and Switch II domains of Ras, resulting in side-chain 
rearrangements centered on Ala59, which inserts itself into the Mg2+ binding cleft [80].  
Additional structural shifts found in the phosphate-binding loop cause a massive 
enhancement of GDP ejection rates and preferential replacement with a GTP molecule 
in the nucleotide binding site [80].   
 
1.6 - Post-translational Modifications of Ras 
 
 A pioneering study centered on viral form of H-Ras showed that the protein 
localized strongly to the cell membrane [81].  Soon afterwards, another report 
demonstrated that the viral H-Ras protein localized to the cell membrane in response to 
lipid modifications on the protein’s C-terminus [82].  In 1984, a study described a 
correlation between lipid modifications and Ras function and showed that viral H-Ras 
proteins had to undergo a lipid modification and integrate into cellular membrane in order 
to drive cellular transformation [83].  This hypothesis also held true for the eukaryotic H-
Ras protein, and the investigation concluded that C-terminal processing and membrane 
recruitment of Ras is a prerequisite to its subsequent biological activation [84].   
 The biochemical reactions that lipidate Ras took several years to fully identify 
and required a wide array of biological and biochemical experimental systems.  Even 




each contain a conserved CAAX sequence (Figure 4).  A farnesyl pyrophosphate moiety 
is covalently attached to the cysteine residue of a cytosolic Ras protein by a 
farnesyltransferase (FTase) [85-87].  The farnesylation is followed by proteolytic 
cleavage of the last three amino acids by the Ras-converting enzyme-1 (RCE1), and 
finally isoprenylcycteine carboxyl methyltransferase 1 (ICMT1) methylates the last Cys 
residue [88].  At this point, a palmitoyltransferase (PTase) transfers a palmitoyl moiety to 
the Cys residues slightly upstream of the C-terminus, and the insertion of Ras into the 
membrane is stabilized [88]. 
 While C-terminal processing of the CAAX sequence appeared to be essential for 
the association of Ras with the cellular membrane, studies of alternate splice variants of 
Ras identified a second signaling domain that allows for full membrane recruitment and 
full Ras function [88].  K-Ras-4B contains a string of positively charged Lys residues 
upstream of the C-terminus.  This structural feature can be sufficient to attach the protein 
to the membrane.  However, the prenylated H-Ras, N-Ras, and K-Ras-4A each require a 
further palmitoylation step where a palmitoyl moiety is attached to the C-terminal Cys 
residue before anchoring into the membrane is fully stabilized.  Enzymes that catalyze 
these modifications later become attractive targets for the development of “Anti-Ras” 
drug therapies [20]. 
 
1.7 - Ras Activates a Wide Range of Effectors 
 
 Even though Ras was heavily studied during the 1980’s, at that time Ras’s role in 
cellular signaling remained largely unknown.  It changed with a key observation from a 
study using a microinjection of Ras proteins into rat-embryonic fibroblasts that resulted in 










Figure 4.  Ras Farnesylation - All Ras family members contain a CAAX sequence on 
the C-terminus.  A farnesyl pyrophosphate moiety is covalently attached to a cytosolic 
Ras protein by a farnesyltransferase (FTase).  This is followed by the proteolytic 
cleavage of the last three amino acids of Ras.  Finally, the last Cys residue is methylated 
and a palmitoyltransferase (PTase) transfers a palmitoyl moiety onto the Cys residues 
slightly upstream of the C-terminus , which facilitates and stabilizes Ras’s insertion into 
the membrane.   
Reprinted by permission from Macmillan Publishers Ltd: [Nat Rev Mol Cel Biol] 
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phospholipids into fatty acids and is implicated in the production the secondary 
messenger, arachidonic acid [89].  Subsequently, additional evidence supported the 
hypothesis that excessive Ras activation leads to oncogenic transformation [90-92].  At 
the time, it was determined whether these cellular responses were direct downstream 
reactions to Ras signaling, or pleiotropic effects from over-expression of Ras [90-92].  In 
1988, a landmark report was published demonstrating that specific inhibition of a 
downstream target of Ras disrupts Ras-induced signaling, suggesting that downstream 
cellular effectors are critical for Ras to induce its biological effects [93].  Thus, the term 
“Ras Effector” was coined for proteins that Ras acts on to propagate cellular signaling 
(Figure 5).   
 The first bona fide mammalian Ras effector identified was the RAF1 Ser/Thr 
kinase [94-97].  In response to mitogenic stimulation, RAF1 was shown to activate the 
mitogen-activated protein kinase (MAP Kinase) signal cascade [98].  All three Raf 
isoforms (cRaf, B-Raf, and A-Raf) are capable of direct activation of the 
MAPK/extracellular signal-regulated kinases (MEK1/2 kinases) [98].  These, in turn, 
activate the extracellular signal-regulated kinases (ERK1/2), which subsequently 
activates the E26-transcription factor proteins (ETS) among other proteins.  ETS targets 
genes involved in cell proliferation and differentiation.  However, over-stimulation of ETS 
targets is tumorigenic and results in an oncogenic transformation.  This pathway is a 
basic template for many signaling cascades that arise at the plasma membrane and 
terminate in the nucleus.  However, exactly how Raf was recruited to the membrane and 
activated by mitogenic receptors remained a mystery until a yeast two-hybrid study 
identified Ras and Raf as direct binding partners [96].   Further experiments showed that 
Ras-GTP binds preferentially with Raf when compared to Ras-GDP, suggesting that Ras 
is the link that transmits signals from mitogenic receptors into the MAPK pathway, and 










Figure 5.  Ras Activated Effectors - Ras activates a wide range of effectors in the cell.  
While most of these drive growth and proliferation, there are some that activate 
apoptosis and senescence.  The challenge in understanding Ras signaling lies in 
determining what is the net result of the Ras signal is and how different cellular contexts 
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 Another Ras effector discovered by a yeast two-hybrid screen is 
phosphoinositide 3-kinase (PI3K) [99].  PI3K is involved in the activation of AKT as well 
as regulation of the actin cytoskeleton by growth factors such as PDGF and insulin [100-
102].  Just as Ras requires activation of the MAPK pathway to induce transformation, it 
also requires activation of PIK3 to induce transformation of NIH 3T3 cells [99].  These 
studies laid the groundwork for future experiments concluding that the anti-apoptotic 
effects of Ras stimulation were driven by the pro-survival activities of PIK3 signaling that 
propagates through a cascade involving the Ser/Thr kinase AKT and the transcription 
factor NF-κB (nuclear factor-κB) [103-105].    
 Another direct Ras effector, RalGDS (ral guanine nucleotide dissociation 
stimulator), was also discovered using a yeast two-hybrid system in 1993 [106].  RalA 
and RalB share 46-51% sequence identity with Ras and are members of the Ras 
superfamily of small GTP-ases [107].  RalGDS was found to specifically catalyze 
nucleotide exchange on both RalA and Ral B, but not on other small GTP-ases [108].  
Activation of RalGDS by Ras results in a cooperative activation of Ral.  It is believed that 
active Ras drives transformation primarily through the binding and activation of RAF, 
PI3K, and RalGDS.  However, Ras can bind to numerous other downstream effectors 
and modulate many cellular activities including endocytosis, actin organization, 
cytokinesis, autophagy, gene transcription, and second messenger production [108].  
 In 2001, phospholipase C-ε (PLCε) was identified as a direct effector of Ras 
[109].  PLCε is a key mediator of both Ca2+ signaling and activation of Protein Kinase C 
(PKC).  Activation of PLCε enables it to cleave phosphatidylinositol 4,5-bisphosphate 
into inositol-1,4,5-triphosphate and diacylglycerol (DAG).  This cleavage releases Ca2+ 
and activates PKC.  PLCε contains a CDC25 domain, also known as a RasGEF domain.  
This suggests that molecule upstream of Ras acting as an exchange factor.  In fact, 




 About a year passed following the identification of PLCε as a Ras effector before 
Channing Der and colleagues published a study that TIAM1 (T-cell lymphoma invasion 
and metastasis-1) is also a member of the Ras effector family [111].  TIAM1, a Rac-
specific GEF, preferentially binds GTP-bound Ras through a conserved Ras-binding 
domain leading to activation of Rac in a PI3K-independent manner [111].  Thus, TIAM1 
can operate as an effector that directly mediates the Ras activation of Rac.  Rac, much 
like Ras, is a small GTP-ase signaling protein and has a role in regulating of cell motility, 
growth, and invasion.   
 Ras interaction/interference protein-1 (RIN1), acute lymphoblastic leukemia-1 
(ALL-1) fused gene on chromosome 6 (AF-6), and the Ras association domain-
containing family (RASSF) proteins are some of the lesser-known and more poorly 
defined Ras effectors.  While AF-6 was shown to be involved in mediating transformative 
cytoskeletal effects of Ras [112], the other two protein families (RIN1 and RASSF) have 
an unexpected ability to block Ras transformation (Figure 6).  RIN1 was originally 
described as a Ras effector in 1991 and was the first Ras binding partner with the ability 
to block Ras transformation [113, 114].  The affinity of the interaction between Ras and 
RIN1 is remarkably high and suggests that RIN1 competes with Raf for Ras binding 
[115].  Other models propose that RIN1 triggers endocytosis of Ras-stimulating growth 
factor receptors, such as EGFR [116].  Loss of this negative Ras effector has recently 
been discovered in breast-tumor cell lines, and restoration of RIN1 expression blocked 
anchorage-independent growth in vitro and tumor formation in vivo [117].  Similarly to 
RIN1, loss of expression of another family of negative Ras effectors, the RASSF family, 













Figure 6.  Balancing Ras Signaling - Small subset of Ras effectors that show the 
importance of negative Ras effectors.  Perhaps one of the roles of negative Ras 
effectors is to protect the cell from over-stimulation of Ras by activating pro-apoptotic 
genes.  Accordingly, loss of these negative Ras effectors removes key protection 
elements against Ras mediated transformation.  However, the mechanisms of negative 





Reprinted	  by	  permission	   from	  Macmillan	  Publishers	  Ltd:	  [Oncogene]	   (Cox,	  A.D.	  and	  C.J.	  Der,	  The	  dark	  
side	  of	  Ras:	  regulation	  of	  apoptosis.	  Oncogene,	  2003.	  22(56):	  p.	  8999-­‐9006.)	  Copyright	  2003	  




1.8 - RASSF Family Proteins 
 
 Raf and PI3K interact with Ras through their Ras-binding domains, termed RBD 
and PI3K-RBD, respectively [118].  However, there is another group of Ras effectors 
which share a conserved motif identified as the RalGDS/AF-6 Ras association (RA) 
domain [119].  This domain is found in RalGDS, AF6, and more recently in the Ras-
association domain family (RASSF).  The RASSF family of tumor suppressors is a group 
of non-catalytic proteins encoded by ten genes, each expressing multiple splice variants 
[120].  The RASSF family currently consists of RASSF1, RASSF2, RASSF3, RASSF4, 
NORE1A (RASSF5), RASSF6, RASSF7, and RASSF8.  The founding member was the 
Novel Ras Effector 1A (NORE1A), designated RASSF5, which binds directly to Ras in a 
GTP-dependent manner [120].  Characterization of RASSF1 proteins followed closely 
behind that of NORE1A and they received much attention after both of them were 
identified as important physiological tumor suppressors [121].   
The role of RASSF1A in tumor suppression was first identified when Loss of 
Heterozygosity (LOH) studies centered on lung, breast, and kidney tumors identified 
several loci on chromosome 3p that likely contained one or more tumor suppressor 
genes [118].  Homozygous deletions in lung and breast tumor cell lines narrowed the 
region of 3p21.3 down to a 120kb region in which 8 genes were coded [122, 123].  The 
genes CACNA2D2, PL6, 101F6, NPRL2/G21, ZMYND10/BLU, RASSF1/123F2, FUS1, 
and HYAL2 were each subjected to in-depth genetic analysis; however, these tests 
failed to identity any mutations [118].  While no candidate point mutations were found, 
the promoters of the RASSF family were often found to be excessively methylated in 
tumors, resulting in their suppressed transcription. 
Members of the RASSF family of proteins share a set of highly conserved 




cell.  The first 6 members of the RASSF family, RASSF1-RASSF6, all contain a variable 
N-terminus but share conserved C-terminal motifs containing a Ras-association (RA) 
domain of the RalGDS/AF-6 class and a specialized coiled/coil domain named SARAH 
as it mediates interactions with Salvador, RASSF, and Hippo proteins (Figure 7) [118].  
The RA domain is responsible for interactions with Ras and other small GTP-ases, while 
the SARAH domain mediates protein-protein interactions that are integral in interactions 
with the Hippo pathway inducing cell cycle arrest and apoptosis [10].  Even though the 
RASSF family all share considerable structural homology, studies show that individual 
members of this family perform unique functions in tumor suppression [124].  Although 
RASSF1A has been the best studied, another member of the RASSF family, RASSF5 or 
NORE1A, appears to be a powerful tumor suppressor, although its full understanding of 
its tumor suppressive functions has not been achieved. 
 
1.9 - The Tumor Suppressor NORE1A (RASSF5) 
  
NORE1A (Novel Ras Effector 1 or RASSF5) was the first member of the RASSF 
family discovered and is roughly 50% identical to the relatively well-characterized 
RASSF1A tumor suppressor [125, 126].  In human tumors, NORE1A expression is 
frequently downregulated by promoter hypermethylation or calpain mediated proteolysis 
(Figure 8) [11, 12, 126, 127].  Additionally, the NORE1A gene locus has been reported 
to undergo a Loss of Heterozygosity (LOH) in some primary tumors [128].  Moreover, 
loss of NORE1A via a genetic translocation results in a familial human cancer syndrome 
[15].  Studies on NORE1A in vitro show that exogenous expression of NORE1A can 
promote apoptosis and cell cycle arrest [10, 11, 129].  In human tumor cell lines deficient 









Figure 7.  The RASSF Family of Proteins - The RASSF Family of tumor suppressors is 
comprised of a group of non-catalytic members encoded by ten genes, each expressing 
multiple splice variants.  The first 6 members of the RASSF family share a set of highly 
conserved domains which are integral in defining how these proteins are activated and 
how they function.  The first is a Ras-association (RA) domain where Ras associates 
with these proteins.  The second is a specialized coiled-coil structure called a SARAH 
domain (Salvador-RASSF-Hippo).  
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Figure 8.  Methylation of the CpG Islands Silences Gene Expression - This figure 
shows a representative region of genomic DNA in a normal cell and how methylation can 
affect transcription.  The region shown contains a repeat-rich hypermethylated 
pericentromeric heterochromatin (Left) and an actively transcribed promoter of a tumor 
suppressor gene associated with a hypomethylated CpG island (Right).  In tumor cells, 
repeat-rich heterochromatin becomes hypomethylated and this results in genomic 
instability.  Conversely, hypermethylation of CpG islands results in a tumorigenic 
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effectively blocks the tumorigenic phenotype [11].  Based on these results, NORE1A 
seems to function as a legitimate human tumor suppressor [9, 130, 131].   
 Like other members of the RASSF family, NORE1A contains a Ras Association 
(RA) domain and was identified as a direct Ras binding protein in a yeast two-hybrid 
screen (Figure 9) [120].  NORE1A and Ras form an endogenous complex in cells, and 
NORE1A binds to the Ras oncoprotein in a GTP-dependent manner with affinities similar 
to other known Ras effectors [10, 132].  Therefore, NORE1A is said to be a bona fide 
Ras effector.  Mutations in Ras leading to constitutive activation are known to be 
transforming; however, activated Ras can also actuate pro-apoptotic and senescent 
pathways [7, 14].  NORE1A has been confirmed as a major Ras senescence/apoptosis 
effector; however, the mechanisms underlying this activity are poorly understood [10, 
14].   
Much of the early research on NORE1A was focused on its loss of expression 
and established a correlation of this event in cancer.  In 2004, the first report detailing a 
mechanism of NORE1A mediated tumor suppression was released [129].  Using yeast 
two-hybrid screens, NORE1A was shown to bind the MST1/2 kinases [133].  The MST 
kinases are the core components of the Hippo pathway which is responsible for the 
regulation of cellular apoptosis and senescence (Figure 10) [134].  In the Hippo 
pathway, MST kinases drive the signaling cascade by activating the LATS kinases which 
in turn phosphorylate the terminal transcriptional co-activators, YAP and TAZ [134].  The 
phosphorylation of YAP and TAZ results in their cytoplasmic sequestration and eventual 
degradation [134].  Loss of YAP or TAZ transcriptional activity results in the induction of 
apoptosis (YAP) and an irreversible cessation of the cell cycle termed senescence (TAZ) 













Figure 9.  Domains of the NORE1A Protein - The different protein domains of 
NORE1A are shown above.  The N-Terminus is composed of a Proline Rich domain  
followed by a Cysteine Rich Domain (CRD a.k.a. ZnF) and Central region to the protein.  
The RA domain is found between residues 268 and 361.  This domain binds Ras in a 
GTP dependent manner.  Finally, the C-Terminus contains the SARAH domain where 
NORE1A interacts with other RASSF proteins and elements of the Hippo signaling 
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Figure 10.  The Hippo signaling pathway - The Hippo pathway activates 
apoptosis/senescence when the terminal transcription co-activators YAP and TAZ are 
degraded.  On stimulation, the MST1/2 kinases phosphorylate the LATS1/2 kinases.  
These mark YAP and TAZ for recognition and ubiquitination by the ubiquitin ligase, β -
TrCP.  However, the potential exists for non-canonical regulation of this pathway by 
other kinases and ubiquitin ligases. 
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The Avruch group suggested that Ras/NORE1A drives apoptosis by modulating 
MST kinase activity.  Unfortunately, this study unfortunately failed to conclusively show 
that NORE1A was actually enhancing YAP/TAZ phosphorylation [133].  Ironically, 
Avruch would later publish work that contradicts this report and shows that NORE1A and 
RASSF1A do not activate the MST1/2 kinases; instead he hypothesizes that NORE1A 
and RASSF1A control Hippo signaling by altering substrate availability and localization 
for MST1/2 activation [135].  Therefore, the role of NORE1A in Hippo signaling remains 
controversial at this time.   
Complicating the issue further, activation of the MST kinases is generally 
considered an apoptotic event; however, NORE1A appears to focus more on mediating 
senescence rather than apoptosis [14, 130].  Cellular senescence can be activated by 
several mechanisms, including activation of p53, Rb, and TAZ [136-138].  My lab 
recently published that NORE1A induces cellular senescence through control of p53 
transcriptional activity via HIPK2 [14].  A close analysis of the data suggests that p53 
activation is not the only factor that NORE1A modulates to activate senescence.  
Perhaps the reason NORE1A is such a potent activator of cellular senescence is 
because it can activate multiple senescent pathways. 
 
1.10 - NORE1A and Ras in (Oncogene) Induced Senescence 
 
Normal, untransformed cells are not capable of dividing indefinitely because they 
will eventually undergo a process referred to as cellular senescence [139].  This 
permanent cell cycle arrest restraining uncontrolled proliferation and tumorigenesis of 
cells and is thought be an evolutionally derived protection in higher eukaryotes, 




have undergone senescence remain metabolically active; however, they exhibit 
characteristic changes ranging from altered morphology to increased senescence-
associated β -galactosidase activity [140].  Senescence was first described in cultured 
cells that had exhausted their growth potential after a number of passages in vitro.  In 
1997, a study was published showing how ectopic expression of oncogenic H-Ras in 
normal fibroblasts permanently arrested the cell cycle, suggesting that the senescence 
response is a fail-safe mechanism protecting the cells from tumorigenic transformation 
[8, 139].   
Oncogene Induced Senescence, abbreviated “OIS”, occurs in the G1 phase of 
the cell cycle and is associated with a significant increase in the protein levels of p53, 
p21, and p16 [8].  Oncogenic activation of Ras activates p53 inducing the senescent 
activity of p16 which activates cell-cycle arrest [8].  Previous reports demonstrated that 
cells lacking functional Rb overexpress p16 [141].  However, these cells were insensitive 
to p16 mediated cell cycle arrest and continued to proliferate [8].  Therefore, Ras-
induced senescence can be bypassed by inactivating the Rb and p53 pathways (Figure 
11) [142].   
Studies indicate that Ras-induced senescence is not an immediate product of 
Ras signaling, but rather a cellular response to aberrant or excessive Ras activity [8].  
When primary human and rodent fibroblasts were microinjected with isolated Ras 
protein, they proliferated and did not immediately enter senescence until after a lag 
period lasting about two days post injection [143-145]. This delayed response is 
consistent with a homeostatic mechanism that suppresses proliferation after prolonged 
hyper-stimulation by Ras mediated, at least in part, by p53 and p16 [8]. 
Activating Ras-induced senescence requires a complex web of multiple, 
















Figure 11.  Ras (Oncogene) Induced Senescence Mechanisms - Ras stimulation in 
normal cells results in an initial wave of proliferation followed by irreversible growth 
arrest (senescence).  Concurrent with growth arrest, there is accumulation of p53 (via 
bypass of MDM2 regulation) and p16 (a CKDI that prohibits G1 to S phase transition and 
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These mechanisms converge on activation of two proteins, p53 and Rb [142].  Yet, 
activation of p53 and Rb alone is not sufficient to activate cellular senescence [142].  Rb 
and p53 are activated in quiescent cells, but these cells are very different from 
senescent cells because their cessation of the cell cycle is reversible.  Perhaps this 
indicates that senescence requires a threshold level of p53 and Rb activity be reached to 
activate the senescent response [142].  Furthermore, in order for p53 and Rb to achieve 
this threshold, these proteins potentially require a collaboration of multiple signaling 
mechanisms [142].  Thus, signal intensity, tissue type, and tissue microenvironment 
might all be factors determining whether the cell activates or suppresses the senescent 
response [142]. 
In normal cells, p53 transcriptional activity increases in response to Ras induced 
senescence [8].  The mechanism remained unknown until 2009, when Diego Calvisi and 
colleagues linked the senescent Ras effector, NORE1A, to p53 activation [130].  The 
study used genomic microarray analysis of HEK-293ecr kidney cells with NORE1A 
expression artificially manipulated to endogenous levels and found alterations in gene 
expression that closely mimicked those found with other known tumor suppressors [130].  
One target, in particular, was the cyclin-dependent kinase (cdk) inhibitor p21CIP1 [130].  
Like NORE1A, over-expression of p21CIP1 induces G1 arrest, which made it a potential 
target for NORE1A mediated signaling [146].  In fact, the study determined that 
NORE1A actually enhances expression of p21CIP1 via the p53 tumor suppressor [130].    
While the study by Calvisi and colleagues identified a plausible physiological role 
in the regulation of cell cycle arrest by p53, a new study identified NORE1A as a key 
component of Ras driven senescence signaling to p53 [14].  The HIPK2 kinase is a 
tumor suppressor that performs a wide range of functions within the cell.  It has been 
shown to regulate apoptosis by directly phosphorylating p53 at the S46 residue, 




also recruit acetyltransferases CBP/p300 and PCAF which can acetylate p53 and 
modulate its transcriptional activity [148, 149].  Interplay between acetylation and 
phosphorylation of p53 likely determines whether p53 activates a more apoptotic or 
senescent cellular program.  CBP/p300 acetylates p53 at residue K382 and PCAF 
targets K320 [14].  Acetylation at K382 in combination with phosphorylation at S46 shifts 
p53 into an apoptotic program; however, without S46 phosphorylation, this K382 
acetylation shifts p53 towards a cellular senescence program [150, 151].  Furthermore, 
acetylation of K320 has been reported to enhance p53 association with the p21CIP1 
promoter, enhancing its expression which results in the activation of cellular senescence 
[152].  In the presence of Ras/NORE1A signaling, HIPK2 promotes the pro-senescent 
transcriptional program by acetylating p53 at K382 and suppressing the phosphorylation 
of p53 at S46 [14].  Moreover, NORE1A induces the pro-senescent acetylation of p53 at 
K320 [14].  Thus, cellular levels of NORE1A indeed play an important role in defining 
how the cells quantitatively and qualitatively modulate p53 in response to different 
stimuli, specifically hyper-active oncogenes [14].   
 
1.11 - Discovering a Novel Role of NORE1A in Tumor Suppression 
 
 To gain a better understanding of the mechanism of action of NORE1A, a yeast 
two-hybrid screen using full length NORE1A as bait identified several potential binding 
partners.  One protein in particular, which scored quite high, was the E3 ubiquitin ligase, 
β-TrCP.  This potential target is intriguing as it is involved in regulating several powerful 
oncoproteins including IκB, β-catenin, and MDM2, and its loss of function has been 
implicated in several cancers [153-156].  In human tumors, β-TrCP is often found over-




κB and Wnt/β-catenin [157].  Adding to this, mutations are rarely, if ever, found in β-
TrCP [158].  Thus, other factors that affect β-TrCP ubiquitin ligase function including, but 
not limited to, the absence of adapter molecules, loss of cooperating kinases, and/or 
loss of protein scaffolding molecules are likely absent in cancers.  Therefore, we 
hypothesize that NORE1A is a central element involved in β-TrCP mediated protein 
ubiquitination and serves as a scaffolding molecule stabilizing collaborating elements to 
β-TrCP, including the kinase, GSK-3β.  
 This dissertation will present data showing that NORE1A does in fact form a 
direct, endogenous complex with β -TrCP.  This complex results in the efficient 
ubiquitination and degradation of the Wnt signaling endpoint, β-catenin.  NORE1A also 
forms an endogenous complex with the GSK-3β kinase, which is responsible for the 
phosphorylation of substrates, marking them for recognition by the β -TrCP ubiquitin 
ligase complex.  A mutant of NORE1A that is unable to bind GSK-3β fails to efficiently 
regulate β-catenin, suggesting that NORE1A is serving as a scaffold molecule for GSK-
3β and β-TrCP.  Additionally, I will show data demonstrating that NORE1A can “split the 
Hippo” by specifically regulating TAZ over its closely related partner, YAP.  In Hippo 
signaling, activation of the MST kinase cascade results in the ubiquitination and 
degradation of the terminal transcriptional co-activators YAP and TAZ.  However, newer 
research reported that GSK-3β can specifically phosphorylate one of the Hippo pathway 
endpoints, TAZ.  While NORE1A was initially implicated in Hippo signaling via interaction 
with the MST kinases, a mutant of NORE1A that fails to bind MST still effectively 
regulates TAZ protein levels in the cell.  Thus, the NORE1A mediated regulation of TAZ 
can occur outside of canonical Hippo signaling.  Furthermore, the mutant of NORE1A 
that fails to bind GSK-3β fails to regulate TAZ, suggesting that NORE1A is also working 




known to be a senescent event, so this novel Ras/NORE1A signaling mechanism 
provides another way for NORE1A to drive oncogene induced senescence.  Finally, data 
will show that NORE1A is a scaffold for GSK-3β and β-TrCP, stabilizing them into a 
novel protein regulatory complex.  Subsequent loss of NORE1A results in an impairment 
of this complex, and knockdown of NORE1A results in increased steady state levels of 
both β -catenin and TAZ protein levels, resulting in a more aggressive oncogenic 






























MATERIALS AND METHODS 
 
2.1 - Overview 
 
 Isolating and characterizing the growth suppressive functions of important human 
tumor suppressor proteins presents several challenges.  These challenges are 
compounded by the fact that many signaling pathways have a significant amount of 
overlap and cross talk.  However, I designed a set of experiments that isolate these 
signaling elements and provide key insight into these signaling networks.  Work detailed 
in this dissertation employs a wide variety of molecular biology and cell/tissue culture 
techniques.  The goal of these experimental methods is to identify and further and define 
the function of the negative Ras effector NORE1A in human tumor suppression.  This 
section will review these materials and methodology in detail.  These discussions will be 
grouped in different classes of procedures including molecular biology, cell culture, and 
biological assays used in this study.   
 
2.2 – Molecular Biology 
 
Polymerase Chain Reaction – DNA amplification for sub-cloning purposes was 
performed using a standard thermocycler by Bio-Rad (Model T100).  PCR reactions 




Polymerase (Invitrogen).  Reaction parameters consisted of a 5 minute segment at 95°C 
to perform the initial melting of the DNA.  Then the reactions were cycled at 95°C for 1 
minute, annealing temperatures between 55° and 62°, and 72°C for 1 min/1kb amplified 
for 35 cycles.  In each case, the annealing temperatures varied slightly with respect to 
the specific primers individual predicted annealing temperatures.  After the cycling, the 
reactions were allowed to undergo the elongation state at 72°C for 7 minutes and then 
the reaction was held at 4°C until further processed.   
 
TA/TOPO Cloning – Amplified DNA fragments were subcloned into pCR2.1-TOPO 
(Invitrogen) or pGEM-T-EASY (Promega) as each specific protocol dictated.  All PCR 
reactions were sequenced after TA/TOPO cloning to ensure no errors were introduced 
by the Taq polymerase during the PCR amplification step. 
 
Restriction Enzyme Digests – DNA subcloning requires restriction enzyme digests to 
allow the alteration of recombinant DNA plasmids.  All enzymes used are from New 
England Biolabs and were used in reactions consisting of DNA, proper prescribed 
buffers (as required), BSA (as required), and enzymes.   Restriction digests were 
allowed to incubate for 1 hour at the proper temperature which was most commonly 
37°C, yet some enzymes require 25°C. 
 
DNA Ligation – To recombine DNA fragments together, a DNA ligation reaction was 
used.  In order for two DNA fragments to be joined together, they must be digested with 
the same restriction enzymes.  After they are digested and purified, the two DNA 
fragments are added to the reaction along with a 10x ligation buffer (NEB) diluted to a 
final concentration of 1x.  T4 DNA ligase (NEB) was then added to the reaction and the 





Agarose Gel Electrophoresis – DNA from PCR and restriction enzyme digests were run 
on 1% agarose gels to separate the linearized fragments by size.  Agarose gels were 
made by adding powdered agarose (SeaKem LE agarose from Lonza Cat#50004) to a 
concentration of 1% by weight into a 1x TAE (Tris-Base, Acetic Acid, EDTA) solution 
(Diluted from a 10x TAE solution purchased from MediaTech Cat#46-010-CM).  
Ethidium Bromide solution (Invitrogen) was then added to the gel solution after melting 
and before casting to allow for the visualization of DNA.  Gels were then exposed to DC 
electric current at roughly 80mA (110V) allowing proper separation of DNA fragments.  
In some instances, retrieval of DNA from the agarose gel was required.  To achieve this, 
the DNA bands were excised and placed into a GenEleute Column (Sigma Cat# 56500) 
and processed as the protocol prescribed.   
 
Bacterial Transformation – Chemically competent bacteria were procured from 
Invitrogen and I used several types of different competency levels including subcloning 
efficiency DH5α, Max Efficiency DH5α, and Chemically and Electrically Competent 
TOP10 E. coli (Invitrogen Cat# 18265-017, 18258-012, C5050-03, and K4580-01).  For 
standard whole plasmid transformation, it is more cost effective to use the subcloning 
efficiency DH5α.  However, when performing plasmid ligations and TOPO/TA cloning, it 
is best to use a higher competency bacterium (Max Efficiency or TOP10 E. coli) as the 
mass of complete ligated plasmid is much lower than that of a whole plasmid 
transformation.  To chemically transform a plasmid into chemically competent bacteria, 
the bacteria was mixed with 200ng up to 1µg of plasmid DNA on ice for 30 minutes.  The 
mixture was then transferred into a 42°C water bath for 30 seconds.  After the heat 




SOC media (Corning Cellgro Cat# 46-003-CR) was then added to the mixture and 
placed at 37°C for 1 hour.  After the outgrowth stage, the mixture was plated on LB agar 
plates containing antibiotics (typically Ampicillin at a final concentration of 100µg/ML or 
Kanamycin at a final concentration of 50µg/mL) matching the resistance markers on the 
transformed plasmid.  The plates were incubated at 37°C overnight.  The next day 
colonies were selected and grown in LB broth media, again supplemented with the 
proper antibiotic at the correct final concentrations listed above, and once again 
incubated overnight at 37°C in a shaker set at 300 RPM.  After the colonies were 
expanded and grown in the LB media, the cultures were processed and the plasmids 
were extracted and purified from the bacteria as described below.   
 
Plasmid Purification (Preparation) – DNA plasmids were extracted and purified from E. 
coli cultures using kits from Qiagen (Mini-Scale Kit Cat# 27106 and Midi-Scale Kit Cat# 
69506 and Midi-Scale Plasmid Kit by Sigma Aldrich Cat# NA0200-1KT).  Mini scale 
plasmid preparations started with a 5mL culture inoculated from a single bacterial 
colony.  This inoculation was grown overnight in LB media at 37°C in proper antibiotics 
per the plasmids resistance marker.  The entire culture was then pelleted using a bucket 
centrifuge spun at 5000 RPM for 15 minutes.  Following centrifugation, the media was 
decanted and the entire pellet resuspended in buffer provided by the kit.  From there, the 
plasmid extraction and purification were carried out according to manufacturer’s 
protocol.  For Midi-Scale plasmid extractions and purifications, a single colony was 
isolated form an LB agar plate and grown for 8 hours in 5mL of LB media containing 
proper antibiotics at 37°C.  The entire culture was then added to 50mL of fresh LB media 
containing necessary antibiotics and incubated overnight at 37°C.  The next day, the 




and the remaining pellet was then processed according to the specific Midi-Scale kit’s 
protocol.  
 
2.3 – Plasmids 
 
pCR2.1-TOPO – This TA cloning system purchased from Invitrogen has a TOPO-
Isomerase attached to each end of the pCR2.1 DNA plasmid.  Isolated PCR fragments 
can be inserted into this vector due to the fact that the Taq polymerase leaves an “A” 
overhang on polymerized DNA fragments.  The vector is designed with “T” overhangs 
allowing for base pair recognition and subsequent isomerization with TOPO to seal PCR 
fragments into the plasmid.  Colonies can be selected with Blue/White x-gal screenings 
to aid in the selection of positive transformants. 
 
pGEM-T-Easy – Working similarly to pCR2.1-TOPO, this system employs a T-4 DNA 
ligase instead of a bound isomerase.  In some instances, this TA vector system was 
more helpful as pCR2.1-TOPO has an internal BglII site, which drops a non-specific 
1.5kb band when digested with BglII that sometimes interferes with the retrieval of 
inserts with BglII cloning sites.  pGEM-T-Easy contains no such BglII site, and allows for 
easier cloning of elements requiring BglII restriction digests. 
 
pEGFP-C1 – This mammalian expression construct is driven by a CMV promoter and 
allows for an N-Terminal GFP (Green Fluorescent Protein) tag to be fused to cDNAs 





pmKate2-C – This plasmid backbone is practically a base for base copy of pEGFP-C1 
except this expression construct expresses an RFP (Red Fluorescent Protein) tag fused 
with cDNAs inserted into its multiple cloning site.  This construct was purchased from 
Evrogen. 
 
pCDNA3 – One of the more ubiquitous mammalian expression plasmids used in 
research today, this construct was purchased from Invitrogen.  It pairs a CMV promoter 
upstream on a multiple cloning site.  One of its downfalls is that it does not have a 
segment that expresses a fused epitope tag.  Thus, the need to create a pCDNA3 
construct with fused epitope tags would become useful in future experiments. 
 
pCDNA3-HA – Using annealed polylinkers inserted into the multiple cloning site of 
pCDNA3, the construct now was altered to have an in-frame BamHI fused to a 5’-HA 
epitope tag which allows for insertion of genes by a BamHI/EcoRI digest.  Expression of 
inserted genes results in a fused HA tag on the N-terminus of proteins. 
 
pCDNA3-Flag – Similarly to the pCDNA-HA plasmid, the pCDNA-Flag expression 
construct was created in much the same way, except the inserted polylinker expresses 
the Flag epitope tag.  The construct allows for inserts to receive an N-terminal Flag tag 
fused to any expressed protein that is in frame with the 5’ BamHI restriction site.  Again, 





NORE1A – Full length human NORE1A cDNA was obtained from Origene (Rockville, 
MD).  The NORE1A cDNA clone was then PCR amplified with primers “hNore1a5’” with 
the sequence 5’ – GCAGATCTATGGCCATGGCGTCCCCGGCCATC – 3’ and 
“hNore1a3’” with the sequence 5’ – GCGAATTCTTACCCAGGTTTGCCCTGGGATTC – 
3’ to yield a 1273 base pair DNA fragment with 5’-BglII and 3’-EcoRI restriction sites.  
The fragment was TOPO cloned into pCR2.1-TOPO for sequencing and subcloning 
applications.  Post-analytical confirmation, the pCR2.1-TOPO-NORE1A plasmid was 
digested with BglII and EcoRI and ligated into a BamHI/EcoRI digest of a pCDNA3 
(Invitrogen) mammalian expression construct containing an in-frame 5’-HA tag as well as 
a pCDNA3 construct containing an in-frame 5’-Flag epitope tag.  The BglII/EcoRI 
digested NORE1A fragment was also ligated into both GFP (pEGFP-C1) and RFP 
(pmKate2-C) digested with BglII and EcoRI.   
 
NORE1A 92-94A Mutant – I developed a triple point mutant of NORE1A mutating the 
92nd to 94th amino acids from Arg to Ala.  To achieve this, two separate NORE1A 
fragments were created and ligated together disrupting the 92-94th amino acids.  The 
first fragment, termed “Upper Fragment” was PCR amplified from the full length 
NORE1A cDNA with primers “hNore1a5’” and “Nore3’RMut” with sequence 5’ – 
CTGAGCTCCAGGCGCTGCGGCCAGTCTCTGCTGCAGACCAGG – 3’.  This yielded a 
297 base pair DNA fragment was TOPO cloned into pCR2.1-TOPO for sequencing and 
subcloning applications.  The “Lower Fragment” was amplified using primers 
“Nore5’RMut” with sequence 5’ – CTGGAGCTCCCCGACCCCGCGACGTG – 3’ and 
“hNore1a3’” yielding a 982 base pair band.  This fragment was also TOPO cloned into 
pCR2.1-TOPO for sequencing and subcloning applications. The mutation was made 




installed a SacI restriction site.  To complete the mutated cDNA, the Upper Fragment 
was ligated into pEGFP-C1 using BglII and SacI.  The Lower Fragment was then 
inserted into pEGFP-C1-NORE1A-RMut-UpperFragment by restriction digests with SacI 
and EcoRI and subsequent T4 DNA ligations.  Combining the Upper and Lower 
Fragments allowed for the mutation of the 92-94th amino acids and completion of the 
cDNA.  The completed NORE1A92-94A mutant was then subcloned from pEGFP-C1-
hNORE1A92-94A Mutant (BglII/EcoRI) into pCDNA3-HA (BamHI/EcoRI), pCDNA-Flag 
(BamHI/EcoRI), and pmKate-2C (BglII/EcoRI).   
 
NORE1AΔSARAH – The SARAH domain of NORE1A lies on the C-terminal end of the 
protein.  To remove this domain, full length NORE1A was PCR amplified with primers 
“hNore1a5’” and “hNore1aDeltaSARAH3’” with sequence of 5’ – 
GCGAATTCTTATTAATTCTCCTTTAGCACAAAGC – 3’.  The resulting DNA fragment 
was then TA cloned into pGEM-T-Easy for sequence analysis and subcloning 
applications.  After sequence analysis showed that the polymerase produced an error 
free product, the pGEM-T-Easy-NORE1AΔSARAH was digested with BglII and EcoRI 
and ligated into pCDNA-HA (BamHI/EcoRI), pCDNA-Flag (BamHI/EcoRI), pEGFP-C1 
(BglII/EcoRI), and pmKate2-C (BglII/EcoRI).   
 
H-Ras12Val – Constitutively activated H-Ras was expressed with two different tags.  
pCGN-HA-H-Ras12V was created by cloning the full-length H-Ras12V cDNA as a 
BamHI/EcoRI fragment into the pCGN-HA vector [159].  This cDNA fragment was also 
sub-cloned into pmKate-2-C using that vector’s BglII/EcoRI sites yielding the pmKate-2-




shNORE1A – NORE1A shRNA constructs (Cat# RHS4531-EG83593) were obtained 
from Open Biosystems (Rockford, IL).   
 
β-catenin – GFP-β-catenin was generated by a PCR amplification of the human β-
catenin cDNA (Addgene #16828) with primers “B-Cat5’BamHI” with sequence 5’ – 
GCAGGATCCATGGCTACTCAAGCTGATTTG – 3’ and “B-Cat3’SalI” with sequence 5’ – 
GCGTCGACCTTACAGGTCAGTATCAAACCAG – 3’ making a 2.7kb PCR fragment.  
The PCR fragment was TA cloned into pGEM-T-Easy (Promega) for sequencing and 
subcloning applications.  After sequence verification, pGEM-T-Easy-β-catenin was 
digested with BamHI and SalI and ligated into pEGFP-C1 using the same restriction 
sites. 
 
β-TrCP - β-TrCP human cDNA was obtained from Addgene (#4489).  Using primers “B-
TrCP5’BamHI” with sequence 5’ – GCGGATCCATGGACCCGGCCGAGGCGGT – 3’ 
and “B-TrCP3’SalI” with sequence 5’ – 
GCGTCGACTTATCTGGAGATGTAGGTGTATGTTCG – 3’, the cDNA clone from 
addgene was PCR amplified and the product was TA cloned into pGEM-T-Easy for 
sequence confirmation and subcloning applications.  After sequence verification, the 
pGEM-T-Easy-β-TrCP plasmid was digested with BamHI and SalI and ligated to pEGFP-





β-TrCPΔFBOX – The dominant negative β-TrCP, GFP-β-TrCPΔFBOX, was a generous 
gift from Dr. Tianyan Gao, Associate Professor of Molecular & Cellular Biology at the 
University of Kentucky, who kindly shared his plasmid with us. 
 
TAZ – We procured the full length, wild-type HA-TAZ mammalian expression plasmid 
from Addgene (#32839). 
 
YAP – We purchased a YAP1 expression construct, pEGFP-C3-YAP1, from Addgene 
(#17843) and an RFP-YAP2 was a generous gift from Dr. Howard Donninger, Assistant 
Professor of Medicine at the University of Louisville. 
 
GSK-3β - We obtained the HA-GSK-3β and an un-repressible HA-GSK-3β-
S9Amammalian expression constructs from Addgene (#14753 and #49491). 
 
pGL3-BAR-Luc – This luciferase reporter construct containing a β-catenin Activating 
Region (BAR) promoting element upstream of a luciferin response element allowed us to 
examine β-catenin transcriptional activity in cell systems.  This plasmid was a kind gift 
from Randall Moon at the University of Washington, WA. 
 
8xGTIIC-Luc – This reporter for TEAD transcriptional activity was obtained from 
Addgene (#34615) and was used to examine YAP and TAZ transcriptional activation of 





TK-renilla – The renilla luciferase control plasmid was obtained from Promega (Madison, 
WI).  This construct was co-transfected with all luciferase reporters to provide a readout 
for transfection efficiency in luciferase assays as the Renilla reporter is constitutively 
expressed in mammalian cells.  Furthermore, while the main reporter plasmid responds 
to the luciferase reaction buffer, renilla does not.  Instead, the TK-renilla construct reacts 
to the “stop and glo” reagent, allowing for the use of a dual reporter system and separate 
RLU readouts contained in the same reaction mix. 
 
2.4 – Antibodies 
 
Mouse-Anti-HA – The antibody against the HA epitope tag was purchased from Covance 
(Cat# MMS-101P).  For detection of proteins in on a Western blot, the antibody was 
diluted at 1:5000 in 5%Milk/TBST (TBS-Tween - 50mM Tris-HCl, pH 7.4, 150mM NaCl, 
0.1% Tween 20) and the blot was incubated in the antibody solution overnight at 4°C.  
The blots were then probed with a Sheep-Mouse-IgG-HRP (Amersham Cat# NA931-
1ML) secondary antibody diluted at 1:20000 in TBST for one hour at room temperature 
and detected by West Pico Enhanced Chemi-Luminescence  (Pierce Cat#34080). 
 
Mouse-Anti-GFP – The antibody detecting the GFP-epitope tag was purchased from 
Santa Cruz Bio-Technology (Cat# SC-9996).  For detection of proteins on a Western blot 
containing a GFP epitope tag, the GFP-antibody was diluted at 1:200 in a 5%Milk/TBST 
solution.  The blot was incubated in the antibody solution overnight at 4°C.  After 




secondary (Amersham) at a dilution of 1:15000 in TBST for 1 hour at room temperature 
and detected by West Pico ECL.   
 
Rabbit-Anti-RFP (Kate) – For detection of the Katushka (pmKate-2-C RFP Epitope Tag), 
I used the Anti-tRFP antibody from Evrogen (Cat#AB233,234).  This rabbit polyclonal 
antibody was incubated overnight at 4°C at a dilution of 1:2000 in a 5% BSA/TBST 
solution.  The blots were then probed with a Goat  Anti-Rabbit secondary antibody (KPL) 
at a dilution of 1:10000 in TBST for 1 hour at room temperature and detected using West 
Pico ECL (Pierce). 
 
Mouse-Anti-Flag – For detection of the Flag epitope tag, I used an Anti-Flag primary 
antibody was purchased from Sigma Aldrich (Cat# F1804).  This antibody was diluted at 
1:1000 in a 5%Milk/TBST solution and incubated on the Western blot overnight at 4°C.  
After incubation in the primary antibody, the Western blot was exposed to a Mouse-IgG-
HRP secondary (Amersham) antibody at a dilution of 1:15000 in TBST for 1 hour at 
room temperature and detected by West Pico ECL. 
 
Rabbit-Anti-Human-β-TrCP – Detection of endogenous β-TrCP was performed by an 
Anti-β-TrCP primary antibody purchased from Cell Signaling Technology (Cat# 4394).  
Western blots were incubated in the Anti-β-TrCP antibody at a dilution of 1:2500 in a 5% 
BSA (Sigma Aldrich Cat# A3059-100G)/TBST solution overnight at 4°C.  After incubation 
in the primary antibody, the blot was then exposed to a Goat Anti-Rabbit-HRP secondary 
antibody (KPL Cat# 374-1506) at a dilution of 1:20000 in TBST for 1 hour at room 





Rabbit-Anti-Human-β-catenin – Endogenous β-catenin proteins were detected on 
Western blots using an Anti-β-catenin antibody from Cell Signaling Technology (Cat# 
8814).  The antibody was diluted into a 5%BSA/TBST solution at 1:2000 and incubated 
on the blot overnight at 4°C.  The blot was then exposed to a Goat Anti-Rabbit-HRP 
secondary antibody (KPL) at a dilution of 1:20000 in TBST for 1 hour at room 
temperature and developed using West Pico ECL. 
 
Rabbit-Anti-Human-phospho-β-catenin (Ser33/37 Thr41) – To detect the fraction of β-
catenin that was phosphorylated by GSK-3β, I used an antibody against Phospho-β-
catenin on residues Ser33/37 and Thr41 purchased from Cell Signaling Technology 
(Cat# 9561).  Western blots were exposed to this antibody diluted at 1:2500 in a 
5%BSA/TBST solution overnight at 4°C.  The Goat Anti-Rabbit-HRP was subsequently 
applied at a dilution of 1:20000 in TBST for 1 hour at room temperature and the blot was 
detected using West Pico ECL. 
 
Mouse-Anti-NORE1A – Monoclonal NORE1A antibodies were a gift from A. 
Khokhlatchev (University of Virginia, Richmond, VA) and were raised against human 
NORE1A amino acid residues 119-416.  This antibody was used for detection of 
NORE1A on Western blots and also for immunoprecipitations (IP).  For Western blot 
detection, the antibody was added to a 5% Milk/TBST solution at a 1:500 dilution and 
incubated with the blot overnight at 4°C.  The blot was then probed with a mouse-IgG-
HRP (Amersham) secondary antibody for 1 hour and detected with a West Pico ECL.  
For immunoprecipitations, 1mg of whole cell lysate was incubated with 10µL of the 




immunoprecipitated on Mouse conjugated agarose beads.  For full IP protocol, see 
section “2.7 - Immunoprecipitations”. 
 
Rabbit-Anti-Human-GSK-3β - Endogenous GSK-3β was detected on a Western blot by 
an antibody from Cell Signaling Technology (Cat#9315) diluted 1:2000 in a 
5%BSA/TBST solution.  The antibody solution was incubated with the Western blot 
overnight at 4°C followed by exposure to a Goat Anti-Rabbit-HRP secondary antibody 
diluted at 1:15000 in TBST for 1 hour at room temperature and detected using West Pico 
ECL. 
 
Rabbit-Anti-Human-TAZ – When Western blotting for endogenous levels of TAZ protein, 
an Anti-TAZ antibody purchased from Cell Signaling Technology (Cat# 4883) was found 
to perform well.  This antibody was diluted at 1:1500 in a 5%BSA/TBST solution and 
incubated with the blot overnight at 4°C.  Following the overnight incubation, a Goat Anti-
Rabbit-HRP secondary antibody was added at a dilution of 1:20000 in TBST for 1 hour 
at room temperature and the blot was detected using West Pico ECL.   
 
Rat-Anti-Mouse-HRP TrueBlot Secondary Antibody – Rockland’s TrueBlot product line is 
an HRP conjugated immunoblotting detection reagent that does not detect heavy and 
light chain IgG bands.  This technology is very useful when using agarose-conjugated 
beads that are bound with mouse or rabbit secondary antibodies and yields a much 
cleaner blot.  In some instances, this secondary antibody was used instead of the 
standard HRP-mouse secondary antibody listed above.  When the Mouse TrueBlot 
(Rockland Cat# 18-8817-33) antibody was used, it diluted at a 1:2000 dilution in a 5% 






Mouse-Anti-Rabbit-HRP TrueBlot Secondary Antibody – Used in similar applications to 
the Mouse TrueBlot secondary antibody, this Rabbit-HRP (Rockland Cat#18-8816-33) 
secondary also does not detect the heavy and light chain IgG from Rabbit secondary 
antibody conjugated agarose beads.  It is also used at a 1:2000 dilution in 5% Milk/TBST 
solution and exposed on the blot for 2 hours and developed with West Pico ECL. 
 
2.5 – Cell Lines 
 
HEK-293 – This cell line composed of human embryonic kidney cells was derived from 
an aborted human embryo and acquired from ATCC.  These cells transfect very easily 
and allow for a nice functional platform for transgenic experimentation.  This line is 
cultured in DMEM (explained in the next section) supplemented with 10% FBS (Fetal 
Bovine Serum). 
 
HEK-293T – The HEK-293T cells are derived from HEK-293 cells, but they have been 
altered to stably express the SV40 Large T Antigen that can bind SV40 enhancers 
commonly found in expression vectors to increase protein production.  We purchased 
these cells from ATCC.  The Large T Antigen also suppresses p53 and Rb tumor 
suppressive activity allowing for a more tolerable phenotype to transgenic studies.  
These cells are cultured in the same way as the HEK-293 cells. 
 
NCI-H1299 – Also known as H1299, this cell line is a human non-small cell lung 
carcinoma derived from a lymph node and we purchased this line from ATCC.  Similarly 
to other immortalized cells, the H1299 line can divide indefinitely.  These cells have a 




suppressor.  Furthermore, this cell line also contains a point mutant NRAS-Q61K 
resulting in a constitutively activated Ras signaling phenotype.  These cells are cultured 
in RPMI cell growth medium supplemented with 10% FBS. 
 
A549 – These cells are adenocarcinomic human alveolar basal epithelial cells derived 
from the removal and culture of cancerous lung tissue and acquired from ATCC.  This 
line also contains a point mutation in KRAS (G12S) resulting in the constitutively 
activation of KRAS signaling.  This line, however, was ideal for studies on cellular 
senescence as they are wild-type for p53 and Rb signaling, two elements known to be 
necessary for the induction of senescence.  These cells are cultured in DMEM 
supplemented with 10% FBS. 
 
HBEC-3KT – These normal Human Bronchial Epithelial Cells were a generous gift from 
Dr. Jerry Shay, The Southland Financial Corporation Distinguished Chair in Genetics, 
Department of Cell Biology, University of Texas Southwestern Medical Center, and were 
used to examine how knockdown of specific members of the RASSF family of tumor 
suppressors along with Ras stimulation results in oncogenic cellular transformation [14].  
These cells require a special growth medium and I selected Keratinocyote-SFM medium 
purchased from Invitrogen. 
 
MCF-10A – This cell line is a non-tumorigenic epithelial cell line derived from human 
mammary gland/breast tissue.  These cells are immortalized without the use of viral 
oncogenes giving them primary cell phenotypes.  I used this cell line extensively to 
perform endogenous co-immunoprecipitations of proteins and makes for an excellent 
system to examine how loss of tumor suppressors along with Ras stimulation can result 




responsive to insulin, glucocorticoids, cholera enterotoxin, and epidermal growth factors.  
MCF-10A require a specialized growth media and were cultured in a 50%/50% mixture 
of DMEM and Ham’s Nutrient Mixture F-12 supplemented with horse serum, insulin, and 
EGF. 
 
2.6 – Cell Culture and Transfections 
 
 All cell culture was processed inside a laminar flow biological safety cabinet per 
protocol from the Department of Environmental Health and Safety, the University of 
Louisville, and the Occupational Safety and Health Administration.  All cells were 
cultured on T-75 and T-25 cell culture flasks (TPP), 100mm and 60mm cell culture 
dishes (Greiner Bio-One), and 6, 12, and 24 well cell culture plates (Greiner Bio-One).  
Different cells cultured sometimes require different culture media as previously listed.  
The descriptions of the media used is as follows: 
 
DMEM – Dulbecco’s Modified Eagle’s Medium was purchased from Corning Cellgro 
(Cat# 10-013-CV) and is composed of 4.5g/L glucose and supplemented with L-
glutamine and pyruvate.  The DMEM was further supplemented with 10% FBS (Valley 
Biomedical) and 1% Pen-Strep Antibiotic (Corning Cellgro Cat# 30-002-CI). 
 
RPMI – RPMI 1640 cell culture medium was purchased from Corning Cellgro (Cat# 10-
040-CV) with L-glutamine.  This medium was further supplemented with 10% FBS 
(Valley Biomedical) and 1% Pen-Strep Antibiotic (Corning Cellgro). 
 
Keratinocyte-SFM – HBEC cells require a special growth media formulation and I 




This kit contains Keratinocyte-SFM medium (Cat# 10724-011) which was supplemented 
with provided supplements 25mg Bovine Pituitary Extract (BPE) (Cat# 13028-014), 
2.5µg human recombinant EGF (Cat# 10450-013), and 1% Pen-Strep Antibiotic (Corning 
Cellgro). 
 
DMEM/Ham’s-F12 50/50 Mix – This media is a 50%/50% mixture of two different cell 
culture growth mediums, DMEM and Ham’s Nutrient Mixture F-12 and was purchased 
from Corning Cellgro (Cat# 15-090-CV).  This medium was further supplemented with 
5% horse serum (Sigma Aldrich Cat# H1270), human insulin (Sigma Aldrich Cat# I9278-
1ML) to a final concentration of 10ug/mL, and recombinant epidermal growth factor 
(Invitrogen Cat# PHG0311) to a final concentration of 10ng/mL, and hydrocortisone 
(Sigma Aldrich Cat# H6909) to a final concentration of 0.5ug/mL.   
 
PBS – Phosphate Buffered Saline was purchased from Corning Cellgro (Cat# 21-040-
CV and #46-013-CM) and used to wash cells and other routine cell culture applications 
as required. 
 
Trypsin EDTA 0.25% - We purchased this trypsin solution (Corning Cellgro Cat# 25-053-
CI) to remove adherent cells from culture dishes and flasks.  Media was removed by 
aspiration from cell culture dishes and washed once with 1xPBS.  The PBS was then 
aspirated and the trypsin-EDTA solution was then added, covering the bottom of the dish 
with a thin layer of solution.  The dishes were then placed back into the incubator for 3-5 
minutes allowing the trypsin to remove adherent cells.  After the cells were removed 
from the flask, the trypsin-EDTA was neutralized with supplemented culture medium and 
the cells were pelleted by centrifugation (5 minutes at 1500 RPM).  The cell pellets were 





RIPA Buffer – For applications where we were not investigating protein/protein 
complexes, I lysed cells in a RIPA Buffer (Sigma Aldrich Cat# R0278).  This buffer 
contains 150mM NaCl, 1.0% IGEPAL® CA630, 0.5% sodium deoxycholate, 0.1% SDS, 
and 50mM Tris pH 8.0.  This buffer allows for efficient cell lysis and exceptional protein 
stabilization for analysis on a Western blot.   
 
G418 Sulfate – For selection of cells expressing a G418 resistance marker, G418 sulfate 
(Corning Cellgro Cat# 30-234-CR) was added to growth media at a final concentration of 
500µg/mL.   
 
Puromycin – For selection of cells expressing a puromycin resistance marker, 
Puromycin dihyrochloride (Sigma Aldrich Cat# P8833-10MG) was added to cell culture 
media at a final concentration of 1µg/mL 
 
MG132 – To inhibit the 26S proteasome, cells can be treated with a chemical named 
MG132 (Sigma Aldrich Cat# C2211-5MG).  To make a working stock of MG132, stock 
powder was dissolved in DMSO to a final concentration of 10mM and used in cell culture 
media at a final concentration of 10µM for 8-24 hours.  The drug is reversible, so care 
must be taken to not let the drug effects fade and time experiments properly. 
 
Cycloheximide – Cycloheximide (CHX) is an antibiotic produced by the S. griseus 
species that inhibits protein biosynthesis in eukaryotic cells.  It inactivates the 
transferase II enzyme that is involved in peptide chain elongation.  It is used in studies to 
analyze protein stability.  Stock powder (Sigma Aldrich Cat# P8833-10MG) was 




inhibit transcription, CHX was added to the cell culture medium at a final concentration of 
20µg/mL. 
 
Farnesyl Transferase Inhibitor (FTI) – FTI-277 was obtained from CalBiochem (LaJolla, 
CA) and was used to chemically inhibit Ras signaling by impeding its ability to bind the 
cell membrane.  The inhibitor was added to cell culture media at a final concentration 
10µM. 
 
Cell Transfections - Cells were transfected using several options available in the 
laboratory.  Commonly the HEK-293, HEK-293T, H1299, and MCF-10A cells were 
transfected with JetPRIME (Polyplus) transfection reagent.  A549 cells were transfected 
with Lipofectamine 3000 Transfection Reagent (Invitrogen) as the JetPRIME reagent did 
not have sufficient efficiency when transfecting this line. Transfection reagent specifics 
and methodology are listed below. 
 
JetPRIME™ - The JetPRIME™ DNA transfection reagent (VWR Cat# 89137-972) is 
described by the manufacturer as a novel and versatile cationic polymer-based reagent 
designed to ensure high DNA transfection efficiency.  JetPrime™ forms positively 
charged complexes with DNA that can penetrate the cell membrane through endocytosis 
and release DNA into the cytoplasm of the cell via the “proton sponge mechanism”.  
Plasmids mostly reach the nucleus when the nuclear envelope disappears during 
mitosis.  1-2µg of specific DNA plasmids were mixed in 100µL (35mm dish) to 200µL 
(60mm dish) of the provided JetPrime™ Transfection Buffer.  To this mixture, 2µL of 
JetPRIME™ was added per 1µg of DNA to be transfected.  The mixture was then 
vortexed for 15 seconds and the transfection mixture was allowed to incubate for 10 




allowed to sit for at least 6 hours.  After 6 hours, culture media could be changed if 
complications with cytotoxicity arise. 
 
Lipofectamine 3000® - This transfection reagent is a proprietary lipid formulation 
purchased from Invitrogen (Cat# LC3000015).  Lipofectamine 3000® is especially 
designed for hard to transfect cells, and I found this to be much more successful at 
transfecting A549 cells than when I used JetPRIME™.  To begin the process, cells were 
seeded to be 70-90% confluent prior to addition of transfection reagent.  Two tubes each 
containing 125µL of Opti-MEM (Invitrogen Cat# 31985062) were prepared.  The 
Lipofectamine 3000® was then added to each tube, 3.75µL in the first tube and 7.5µL in 
the second.  Next, a DNA master mix was prepared by diluting 1-2µg of each DNA 
plasmid into 250µL Opti-MEM and adding 2µL of P3000™ per 1µg of DNA.  This 
solution was mixed well and then 125µL was added to each previously prepared tube 
containing the Lipofectamine 3000® reagent.  These mixtures were then allowed to sit 
for 5 minutes at room temperature, making a high and low lipid dose of transfection for 
each dish.  After the incubation, both high and low mixtures were added to the proper 
dish and allowed to sit on the cells for 6 hours.  After this time, the culture media was 
changed and the cells incubated overnight to begin expressing recombinant plasmids. 
 
2.7 – Immunoprecipitation 
 
 One of the best ways to detect and examine how proteins interact with each 
other is the co-Immunoprecipitation assay.  This assay uses an antibody, typically 
conjugated to an agarose bead, to bind and precipitate a specific protein.  The 
precipitation is then analyzed for the presence or absence of other proteins that were 




insufficient cell lysis, inadequate purification of proteins, non-specific precipitation, and 
high background detection.  Caution must be taken at every step to minimize these 
issues.   
 
Immunoprecipitation of Over-Expressed Proteins – Transfected cells were lysed 24 to 48 
hours post-transfection in a modified RIPA buffer.  Modified RIPA buffer is composed of 
50mM Tris-HCl pH7.4, 200mM NaCl, and 1% NP-40.  Cells were plated in 60mm dishes 
for over-expression studies and 350µL of modified RIPA buffer was added to each dish 
to begin the lysis process.  Cells were then scraped and collected in microfuge tubes 
and placed on a rotator for 3 hours at 4°C.  After rotation, each sample was then slowly 
passed through a 25 gauge syringe needle 4 times and then centrifuged at 10,000 RPM 
for 5 minutes at 4°C.  The supernatant was then removed from the insoluble pellet and 
quantified using a Bio-Rad protein quantification assay (Bio-Rad Cat# 500-0006).  To a 
new microfuge tube, 1mg of total protein was added and modified RIPA buffer was 
added to reach a final volume of 1mL.  Agarose beads were then added matching the 
specific epitope tag of one of the over-expressed proteins.  For HA precipitations, I used 
5µL of HA-conjugated agarose beads prepared as the manufacturer’s protocol 
prescribed (Sigma Aldrich Cat# A2095-5ML).  To precipitate the Flag epitope tag, 5µL of 
Anti-Flag M2 Affinity Gel (Sigma Aldrich Cat# A2220-5ML) was prepared according to 
the manufacturer’s protocol and added to the cleared cell lysate.  And finally, for 
precipitation of the GFP epitope tag, GFP-Trap® (Allele Biotech Cat# ABP-NAB-
GFPA100) was used according to manufacturer’s protocol.  In each case, the cleared 
cell lysate was rotated overnight at 4°C with the proper agarose conjugate.  The next 
day, the bead/lysate mixture was centrifuged for 3 minutes at 3000 RPM at 4°C to pellet 
the agarose.  The supernatant was then removed by aspiration and the beads were 




final wash, the beads were resuspended in 10µL of standard RIPA buffer and 5µL of 4x 
LDS (Lithium Dodecyl Sulfate) sample running buffer purchased from Invitrogen (Cat# 
NP0007).  The IP samples and lysate controls were then run on an SDS-PAGE gel and 
analyzed by Western blot. 
 
Immunoprecipitation of Endogenous Proteins – Conversely to over-expressed proteins, 
endogenous proteins do not contain epitope tags and must be immunoprecipitated 
slightly differently than over-expressed proteins.  Cells were lysed in a modified RIPA 
buffer and again 1mg of total cell lysate was set-aside in a final volume of 1mL.  Then a 
primary antibody against the target protein was added and rotated overnight in the 
protein lysate at 4°C.  The next day, an agarose conjugated secondary, typically mouse 
or rabbit (Rockland Cat# 00-8800-25 and 00-8811-25), antibody was added and rotated 
for 2 hours at 4°C to capture the primary antibody/target protein complex.  Then 
mirroring the previously described method, the agarose beads were collected by 
centrifugation at 3000 RPM for 3 minutes at 4°C.  The beads were washed 3 times with 
1mL of modified RIPA buffer.  Following the wash steps, the beads were resuspended in 
10µL of standard RIPA buffer and 5µL 4xLDS sample running buffer.  The IP along with 
controls were analyzed by Western blot. 
  
2.8 – Western Blotting 
 
Sample Preparation – Cell lysates and protein samples were combined with a 4x LDS 
Sample Buffer (Invitrogen Cat# NP0008) containing 10% β-Mercaptoethanol (Sigma 
Aldrich Cat# M6250-100ML) to a final concentration of 1x.  The protein sample/LDS 




protein sample, allowing for a more consistent separation of size in the polyacrylamide 
gel.   
 
SDS-PAGE – Prepared protein samples were then loaded on a pre-cast 4-12% Tris-
Glycine Polyacrylamide Gel (Invitrogen Cat# EC60352BOX) which is immersed in 1x 
Tris-Glycine SDS Running Buffer (Invitrogen Cat#  LC2675-5).  The gel was run at 150V 
until the loading dye reached the bottom of the gel.  The gel was then removed from the 
running buffer and prepared for transfer onto a nitrocellulose membrane. 
 
Nitrocellulose Transfer – The protein gel was transferred onto a 0.2µm pore size 
nitrocellulose membrane by electrophoresis in 1x Tris-Glycine Transfer Buffer (Invitrogen 
Cat# LC3675) supplemented with 20% methanol for 3 hours at 20V DC power. 
 
Western Blot Detection – After transfer, the nitrocellulose filter was blocked in a 5% 
Milk/TBST solution for 30 minutes and then the blot was incubated in primary and 
secondary antibodies as previously explained earlier in this chapter.  After primary and 
secondary antibody probes were complete, the blots were detected using an ECL 
solution and exposed to chemiluminescent detection film. 
 
2.9 – Biological Assays 
 
Luciferase Assay – Dual luciferase assays were performed using reagents from 
Promega’s Dual Lucifease Assay Kit (Cat# E1960) per the manufacturer’s protocol.  
Cells were transfected for 24-72 hours depending on the reporter construct used before 
being lysed in 200µL of the provided passive lysis buffer.  20µL of sample was 




Units) reading following by a secondary standardization RLU reading on a Lumat 9507 
machine from Berthold Technologies.  Data was analyzed with the RLU1 value divided 
by the RLU2 value resulting in a numerical figure representing relative promoter 
activation. 
 
Senescence Assay – One of the hallmarks of cells that have undergone senescence is 
an increase in β-glactosidase activitiy.  The Senescence Detection Kit from BioVision 
(Cat# K320-250) is designed to histochemically detect β-gal activity in cultured cells and 
tissue sections.  A549 cells were plated onto 12-well culture dishes at 40,000 cells per 
well initial seeding.  The next day, the cells were transfected with expression constructs 
to analyze their effects on the induction of cellular senescence.  72 hours post-
transfection, the cells were processed with the Senescence Detection Kit per the 
manufacturer’s protocol.  Five random fields were counted in each well and the number 
of blue cells counted was divided by the total number of cell counted in the entire field.  




















RAS REGULATES SCF-β-TrCP ACTIVITY AND SPECIFICITY VIA NORE1A 
 
3.1 - Introduction 
 
Mutations in the Ras oncogene can be detected in roughly one third of human 
cancers [23].   When activated, the Ras oncoprotein drives growth and transformation by 
binding and activating multiple effectors that stimulate multiple signaling pathways.  
Three of the best characterized cascades are the Raf, PI-3Kinase, and RalGDS effector 
pathways [160].   However, Ras can also impact other signaling pathways important to 
proliferation and development, such as the Wnt/β-catenin signaling pathway [161].  The 
interaction of the Ras and the Wnt/β-catenin signaling pathways is quite complex and 
appears to occur at multiple levels [162-164].  An interesting dichotomy exists, as Ras 
has been reported to exhibit both positive and negative effects on the pathway [162-
164].  Moreover, although synergistic activation of transformation by Ras and Wnt/β-
catenin has been reported, other reports have identified an antagonistic role in 
transformation [163, 164].  How Ras impacts the Wnt/β-catenin pathway is still not fully 
understood.  Nor is the balance of cellular factors that dictate whether a net positive or 
negative effect is observed for Ras on Wnt/β-catenin pathway signaling. 
Similarly to many other oncogenic signaling pathways, members of the Wnt 
signaling pathway can be subdivided in positively and negatively acting components 




of function status in cancer, while the positively active components are found 
constitutively activated [165].  Improper regulation of the Wnt signaling pathway 
transcriptional co-activator, β-catenin, is an oncogenic force in human cancers.  
Beginning with the first observations that β-catenin overexpression could lead to 
malignant transformation and continuing today, the Wnt/β-catenin pathway continues to 
evolve as a central mechanism in tumorigenesis [165]. 
In the canonical Wnt/β-catenin pathway, β -catenin is the terminal executor, 
serving as both a nuclear transcriptional co-regulator and key component of adherens 
junctions [166].  In the absence of Wnt ligand signaling, a multi-protein complex 
consisting of APC, Axin, and GSK-3β, phosphorylates β-catenin.  This phosphorylation 
is necessary for the binding of β-TrCP, the substrate recognition component of the SCF-
β-TrCP ubiquitin ligase complex.  SCF-β-TrCP mediated ubiquitination of β-catenin results in 
its rapid degradation by the 26S proteasome [167].  In response Wnt ligand activation of 
the Frizzled receptor, the GSK-3β phosphorylation complex is destabilized by 
Disheveled family proteins allowing for unphosphorylated β -catenin levels to quickly 
increase in the cytoplasm and translocate to the nucleus.  The nuclear pool of β-catenin 
functions as a cofactor for transcription factors of the TCF/LEF family, modulating genes 
involved in growth and survival [168].    
Beta-transducin repeats-containing proteins (β-TrCP) serve as the E3 substrate 
recognition subunits for the SCFβ-TrCP ubiquitin ligase complexes [157].  The ubiquitin 
proteasome system controls the degradation of the majority of regulatory eukaryotic 
signaling proteins, including proteins that perform central functions in tumorigenesis, like 
β-catenin, IκB, YAP, and TAZ [157, 169].  E3 ubiquitin ligases determine the timing and 
specificity of ubiquitination for substrates and typically target proteins with a very specific 




Beta-TrCP is expressed at relatively low levels in the cell and its function can be easily 
disrupted by the expression of a dominant negative construct, which lacks an F-Box 
domain making it unable to bind the other members of the SCF ubiquitin complex [170, 
171].  Furthermore, the activity of β-TrCP can be controlled by several different cellular 
mechanisms that can alter its localization, relative abundance, and levels of 
phosphorylated substrates [157].  Interestingly, levels of β -TrCP are often elevated in 
tumor cells, yet in these cells β-TrCP fails to properly regulate its usual oncogenic 
substrates, including β-catenin [157, 172].  This suggests that presence or absence of 
other scaffolding elements can alter its ubiquitin ligase activity and/or specificity.  
While cells constitutively synthesize β -catenin to remain ready to respond to 
incoming Wnt signaling, the high turnover rate of β -catenin via the SCF-β-TrCP ubiquitin 
ligase complex maintains the proper balance [173].  Dysfunction in the regulatory 
mechanism of β -catenin is found in many human cancers and mutated forms of β -
catenin which cannot be ubiquitinated by the SCF-β-TrCP ubiquitin ligase are indeed 
oncogenic [168].  By enhancing down-regulation of β -catenin, β -TrCP can serve as a 
tumor suppressor [174].  However, the situation is more complex as β -TrCP has also 
been reported to have oncogenic potential in some situations [175, 176].  This may be 
due to its role in degrading non β-catenin targets such as Claspin [177]. 
Paradoxically, activated forms of Ras are not only powerfully transforming, but 
can also act as powerful stimulators of cell death pathways [7, 126].  Ras induced cell 
death appears to be mediated, at least in part, by members of the RASSF family of 
tumor suppressors, which bind Ras and function death effectors [126].  NORE1A 
(RASSF5) was the first member of the RASSF family to be identified [9].   It connects 
Ras to the pro-apoptotic Hippo pathway, but this does not seem to be essential for its 




ability to promote cell cycle arrest.  NORE1A is expressed in most normal tissues, but its 
expression is lost in many tumors due to epigenetic inactivation, loss of heterozygocity, 
or deregulated proteolysis [10, 118].  NORE1A is considered a bona fide tumor 
suppressor, as a hereditary genetic defect in NORE1A predisposes the human carriers 
to kidney cancer [15].   However, many of the tumor suppressive functions of the 
Ras/NORE1A interaction remain largely uncharacterized. 
We preliminarily identified a direct interaction between NORE1A and β-TrCP in a 
yeast two-hybrid screen. This suggests that either NORE1A is a substrate for SCF-β-TrCP 
or, more interestingly, might connect Ras to the control of the complex.  As SCF-β-TrCP 
modulates the Wnt/β-catenin pathway by targeting β -catenin for degradation by the 
proteasome [174], NORE1A might serve to link Ras to the control of β -catenin protein 
stability and transcriptional signaling.   
Following the preliminary data, I sought to determine the role of NORE1A in the 
control of the SCF-β-TrCP ubiquitin ligase and Wnt/β-catenin signaling.  I now show that 
NORE1A forms a direct, endogenous, Ras regulated complex with β-TrCP allowing Ras 
to stimulate the activity of SCF-β-TrCP towards β-catenin.  The activation of the SCF-β-TrCP 
ubiquitin ligase complex by Ras/NORE1A is substrate specific, as NORE1A had no 
effect on SCF-β-TrCP substrate IκB.  Moreover, NORE1A deficient lung tumor cells exhibit 
enhanced steady state levels of β -catenin and resist the growth inhibitory effects of β -
TrCP.  Therefore, the cellular levels of NORE1A may dictate how Ras modulates β -
catenin and determine the substrate profile of the SCF-β-TrCP ubiquitin ligase.  β-TrCP has 
been reported as an oncogene and as a tumor suppressor in different cell systems.  The 





3.2 – Results 
 
NORE1A forms a direct, endogenous, Ras regulated complex with β-TrCP  
β-TrCP is the substrate recognition component of the SCF-β-TrCP ubiquitin ligase.  
It is expressed as two closely related isoforms, β -TrCP1 and β -TrCP2.  A yeast two-
hybrid screen (Myriad Genetics, Salt Lake City, UT), using full length NORE1A as bait, 
identified β-TrCP1 as a potential direct binding partner.  To determine if this result was 
physiological, I immunoprecipitated lysates from MCF10A cells for NORE1A and 
immunoblotted for the presence of β -TrCP.  Figure (12a) shows that NORE1A and β -
TrCP could be detected in an endogenous complex.  Further studies were then 
performed using exogenously expressed proteins.  HEK-293 cells were co-transfected 
with expression constructs for NORE1A and β -TrCP1.  The cells were then lysed and 
immunoprecipitated for β -TrCP1 and immunoblotted for NORE1A.  The proteins could 
be co-immunoprecipitated (Figure 12b). 
NORE1A is a Ras effector protein, consequently I examined the role of Ras in 
controlling the interaction between NORE1A and β -TrCP1 in similar experiments.  The 
presence of activated H-Ras in the co-transfection enhanced the association between 
NORE1A and β -TrCP1 proteins (Figure 13).  These blots were under-exposed in 
comparison to the blots of Figure 12b. 
 
NORE1A promotes β-catenin degradation via β-TrCP  
As β -TrCP is the substrate recognition component of the major ubiquitin ligase 
















Figure 12.  NORE1A Forms a Protein Complex with β-TrCP - (A) Whole cell lysates 
were prepared from MCF-10A cells and the protein extracts were immunoprecipitated 
(IP) with anti-NORE1A for 16 hours and then immunoblotting (IB) for β -TrCP.  IgG 
incubated with MCF-10A lysate and Ig/NORE1A antibody incubated with lysis buffer 
serve as the negative controls.  Blot of NORE1A levels is not shown due to interference 
from the IgG band.  MCF10A lysate serves as the positive control.  (B)  HEK-293 cells 
were transfected with expression constructs for HA-NORE1A and GFP-β-TrCP1.  Cell 
lysates were immunoprecipitated (IP) with GFP-Trap® Beads (Allele Biotech, San Diego, 






















Figure 13.  Ras Regulates NORE1A Binding with β-TrCP - HEK-293 cells were 
transfected with expression constructs for HA-NORE1A and GFP-β-TrCP1 in the 
presence or absence of an activated form of RFP-H-Ras (12V).  After 24 hours the cells 
were lysed and immunoprecipitated with GFP-Trap® beads before immunoblotting.  A 
shorter exposure of the immunoprecipitation shows that the presence of activated H-Ras 










expression on β-catenin protein stability using transient transfections performed in HEK-
293 cells.  Co-expression of NORE1A suppressed the expression of β -catenin to sub-
detectable levels.   This effect was largely blocked by the 26S proteasome inhibitor 
MG132 (Figure 14).  To further support the MG132 experiment, the transient 
transfections of NORE1A and β-catenin were repeated once more in HEK-293 cells.  24 
hours post-transfection, the cells were treated with cycloheximide.  Dishes were lysed 
over a time course of 24 hours and samples examined by western blot. The results 
confirmed NORE1A was acting at a protein stability level (Figure 15).  In order to 
determine if NORE1A and β-TrCP1 synergize to promote the degradation of β-catenin, I 
partially inhibited the proteasome by adding low levels of MG132 for 6 hours.  Under 
these conditions, the ability of both NORE1A and β -TrCP1 to suppress β -catenin 
expression was impaired rather than abolished.   This allowed us to detect a synergistic 
reduction in β -catenin levels when NORE1A and β -TrCP1 were transfected together 
(Figure 16).  Furthermore, a dominant negative form of β -TrCP1, lacking the F-Box 
domain rendering it unable to confer ubiquitin onto substrates [178], blocked NORE1A 
mediated degradation of β-catenin (Figure 16). 
 To examine the effects of Ras on the system, I included activated H-Ras in the 
transfections, again with attenuation of the proteasome with low levels of MG132.  
Activated Ras enhances NORE1A activity against β -catenin (Figure 17).   As further 
support for the role of Ras in directly modifying the action of NORE1A, I included a 
NORE1A point mutant that is defective for Ras binding in the assay (NORE1ARAMUT) 
[179].  This experiment showed that the effects of Ras were due to its interaction with 
NORE1A (Figure 17).    
NORE1A appears to be regulating β -catenin protein levels through the 














Figure 14.  NORE1A Degrades β-catenin Via the 26S Proteasome - HEK-293 cells 
were transfected with expression constructs for β-catenin and NORE1A.  24 hours post 
transfection, the cells were trypsinized and split into two groups and allowed to rest for 
an additional 24 hours.  One group was then treated with the proteasome inhibitor 
MG132 for 5 hours and the other group was treated with DMSO also for 5 hours.  The 














Figure 15.  NORE1A Decreases β-catenin Protein Stability Independent of 
Transcription - HEK-293 cells were transfected with vector or NORE1A and after 24 
hours split into 6 dishes each.  Cycloheximide was added after a further 24 hours and 
dishes lysed over a time course.   Levels of β -catenin protein were measured by 






















Figure 16.  NORE1A Degrades β-catenin in Cooperation with β-TrCP - HEK-293 
cells were transfected with expression constructs for NORE1A, β-catenin, β-TrCP1, and 
a dominant negative β-TrCP (ΔFBOX) which is unable to ubiquitinate target substrates.  
Low levels of MG132 were added to partially inhibit the 26S proteasome to attenuate the 






















Figure 17.  Ras Regulates NORE1A Mediated Degradation of β-catenin - HEK-293 
cells were transfected with expression constructs for NORE1A, a NORE1A mutant 
unable to bind to Ras (RAMUT), β -catenin, and activated H-Ras.  Relative levels of 










mechanism of action, it would require β-catenin to be polyubiquitinated by β-TrCP, which 
would mark it for proteasomal degradation.  To confirm this, HEK-293 cells were 
transfected with expression constructs for NORE1A and GFP-β-catenin along with a HA-
tagged ubiquitin and treated with MG132.  Incorporation   of ubiquitin into GFP-β-catenin 
could be detected (Figure 18). 
 
NORE1A suppresses β-catenin signaling  
Active β -catenin translocates to the nucleus where it binds the transcriptional 
repressors TCF/LEF, thereby activating specific gene transcription.  To investigate if 
NORE1A has any effect on β-catenin transcriptional activity, NCI-H1299 cells, null for 
NORE1A expression, were transfected and stabilized with a pZIP-HA expression vector 
expressing NORE1A or an empty vector control.  The cells were selected in 400µg/mL 
G481 solution until the selection process was complete.  Then, using an artificial 
promoter sequence that is linked to the luciferase gene was used to analyze 
transcriptional activity for β -catenin activity [180].  This reporter, containing a β -catenin 
activation region (BAR-Luc), was co-transfected with an expression construct for β -
catenin and a Renilla luciferase internal control into the matched pair of NCI-H1299 cells 
stably transfected with vector or NORE1A expression vector.    The NORE1A expressing 
cells showed reduced β-catenin activity (Figure 19a).  
 
Loss of NORE1A expression enhances steady state levels of β-catenin 
The above results suggest that the loss of NORE1A that is so frequently found in 
human tumors should uncouple Ras from the negative regulation of β-catenin.  Thus, the 













Figure 18.  NORE1A Enhances β-catenin Ubiquitination - HEK-293 cells were co-
transfected with expression constructs for NORE1A, β -catenin, and a HA-tagged 
Ubiquitin.  24 hours post-transfection, the cells were lysed and analyzed by Western blot 















Figure 19.  NORE1A Suppresses Wnt Signaling - (A) NCI-H1299 cells stably 
transfected with vector or NORE1A were transfected with an expression construct for β-
catenin along with a β -catenin responsive luciferase reporter (BAR-Luc) and a TK-
Renilla internal control.  Dual luciferase assays were performed and results standardized 
with the Renilla readout (M1/M2).  n = 2 independent experiments, error bars show 
standard error, p = 0.02.  (B) Immunoblot (IB) analysis confirming expression of HA-
NORE1A.  NCI-H1299 +/- for NORE1A expression shows differences in steady state 
expression of β-catenin. Whole cell lysates were prepared and endogenous levels of β-
catenin were analyzed by immunoblot.  Quantification was performed by densitometry 
using QuantityOne software by BioRad is shown above the blot as a ratio.   
 
 





expression.  To test this hypothesis, I examined the levels of endogenous β -catenin in 
the NCI-H1299 NORE1A +/- matched pair.  These cells carry an activated Ras mutation 
and undetectable levels of endogenous NORE1A [181].  Figure (19b) shows that the 
NORE1A negative cells exhibited higher levels of endogenous β -catenin than the cells 
stably transfected with NORE1A.  As further confirmation, I transfected HEK-293 cells 
with shRNA constructs against NORE1A and assayed for the levels of endogenous β - 
catenin protein. Protein levels of β-catenin were elevated in the shRNA transfected cells 
but not in the scrambled shRNA transfected cells (Figure 20a).   
 
NORE1A differentially regulates β-TrCP targets 
To determine if the effect of NORE1A on SCF-β-TrCP is a general activation or a 
specific activation towards a particular sub-set of targets, a second degradation target of 
β-TrCP1, IκB[182], was chosen for analysis.  HEK-293 cells were transfected with 
expression constructs for IκB, β-catenin, and NORE1A.  Western analysis of the protein 
levels showed that while IκB levels remained the same in the presence of NORE1A, 
NORE1A suppressed β-catenin (Figure 21a).  IκB is a negative regulator of NFκB [183].  
If NORE1A promotes its degradation, I should expect NFκB signaling to increase.  
Luciferase assays using HEK-293 cells stably transfected with an NFκB luciferase 
reporter showed that NORE1A does not promote the activation of NFκB (Figure 21b). 
 
NORE1A levels dictate the biological activity of β-TrCP  
β-TrCP has a range of targets and can act as an oncogene or a tumor 
suppressor depending upon the particular cellular milieu [174-177].  The co-factors 











Figure 20.  Loss of NORE1A Enhances Steady State β-catenin Protein Levels - (A)  
HEK-293 cells were transfected with shRNA constructs against NORE1A.  Endogenous 
levels of β -catenin were analyzed by Western blot.  (B) Stably NORE1A shRNA 























Figure 21.  NORE1A/β-TrCP Mediated Ubiquitination is Substrate Specific - (A) 
HEK-293 cells were transfected with expression constructs for NORE1A, β-catenin, and 
IκB. After 24 hours the cells were lysed and assayed for differential protein expression 
by Western blot. Figure is a representative blot of at least two experiments (B).  HEK-
293 cells stably expressing an NFκB luciferase reporter were transfected with HA-empty 
vector and HA-NORE1A.   A slight suppression of activity was observed due to NORE1A 
but quantification showed this was not significant (p = 0.12).  n = 2 independent 








To determine if NORE1A may be one of these factors, I transfected the NORE1A +/- 
NCI-H1299 cell system with β-TrCP1 and selected for the marker carried by the β-TrCP1 
construct.  Figure (22) shows that β-TrCP1 was highly growth inhibitory in the NORE1A 
positive cells but only weakly inhibitory in the NORE1A negative cells.  Quantification is 
shown in (Figure 23). 
 
NORE1A is a key node in the regulation of β-catenin via Ras 
Ras has been reported to exhibit both negative and positive effects on β-catenin 
protein levels [184, 185].  The factors that determine the net effect of Ras on β-catenin 
are not clear.  To determine if NORE1A dictates the effects of Ras on β-catenin, I treated 
the NCI-NCI-H1299 NORE1A +/- cell system with a farnesyl transferase inhibitor (FTI) 
(Figure 24a) that inactivates Ras [186].  NCI-H1299 cells contain an activated form of 
Ras, which allowed us to examine the effects of endogenous Ras activation on 
endogenous β -catenin expression in a NORE1A positive or negative background.  A 
“normal” cell is positive for NORE1A expression and does not have an activated Ras 
signaling pathway.  The levels of β -catenin under these circumstances are shown in 
column four of Figure 24b.  In the presence of a competent activated Ras (no FTI) in 
these NORE1A positive cells, the levels of β -catenin go down (column 2).  However, 
when I remove the FTI from NORE1A negative cells, I observed that the levels of β -
catenin increased (column 1) relative to the levels in the “normal” cells (column 4).  
Thus, the presence or absence of NORE1A may dictate the effects of Ras, positive or 




















Figure 22.  NORE1A/β-TrCP Cooperate to Control Cell Survival - NCI-H1299 cells 
stably expressing NORE1A or an empty vector were transfected with an expression 
construct for β-TrCP1 and selected with G418.  Cell survival was slightly reduced in cells 
expressing NORE1A or β-TrCP alone.  However, when both are co-expressed, cell 
survival is greatly decreased suggesting a synergistic relationship in tumor suppression 
functions. 
 

















Figure 23.  Quantification of NORE1A/β-TrCP Effects on Cell Survival - Figure 22 
shows a representative experiment, Figure 23 shows quantification of live cells after 2 
weeks.  The data is the average to two separate assays performed in duplicate.  The 




















Figure 24.  Inhibition or Ras Farnesylation Impedes NORE1A Mediated β-catenin 
Control - (A) NCI-H1299 cells stably transfected with NORE1A or empty vector were 
treated +/- with a farnesyl transferase inhibitor for 24 hours to inhibit Ras signaling.  
Whole cell lysates were harvested and probed for total levels of endogenous β-catenin.  
A representative blot is shown in (A), quantification of two experiments is shown below in 
(B).  Vector = Ras+/NORE1A-, NORE1A = Ras+, NORE1A+, Vector + FTI = Ras-
/NORE1A-, NORE1A + FTI = Ras-/NORE1A+.   A normal cell would be expected to be 
negative for activated Ras and positive for NORE1A.  Thus, bar 4 is the reference bar.  
Quantification using densitometry was calculated on QuantityOne software from BioRad.  
Values from two separate assays were combined for quantification.  The graph shows 
this data with standard error and p = 0.02. 
Schmidt et al., 2014 





3.3 - Discussion 
 
 NORE1A directly binds activated Ras and serves as a pro-apoptotic Ras effector 
[10, 11].  What's more, NORE1A suppresses tumor cell growth, is frequently inactivated 
in human tumors, and its inactivation is implicated in a hereditary cancer syndrome [15, 
126, 187].  Therefore, it is likely to serve as an important human tumor suppressor.  At 
one point, NORE1A was implicated in the regulation of Hippo signaling as it binds to the 
MST kinases; however, further study revealed that NORE1A fails to activate their kinase 
activity [10, 135].  Furthermore, deletion mutants of NORE1A that cannot interact with 
MST kinases retain the ability to inhibit cell growth and suppress the tumorigenic 
phenotype [129].  Thus, unknown tumor suppressor pathways independent of the classic 
Hippo pathway must also be modulated by NORE1A.   
 β-TrCP is the substrate recognition component for the SCF-β-TrCP ubiquitin ligase 
complex and exists as two closely related isoforms, β -TrCP1 and β -TrCP2.  Under the 
influence of Wnt signaling, it binds and regulates the degradation of the proto-oncogene 
β-catenin [174].  β -catenin has a dual role in the cell serving both as a component of 
adherens junctions in the cytoplasm and as a transcriptional co-regulator in the nucleus 
modulating the function of the TCF/LEF transcription factors [188].  The Wnt/β-catenin 
pathway plays key roles in development and tumorigenesis, and mutations in the system 
leading to the excessive accumulation of β -catenin have been identified at high 
frequency in human tumors [168, 188, 189].   
 Aberrant activation of the Ras pathway is one of the most common defects 
observed in human cancers [30].  Over a decade of study has revealed multiple, subtle 




poorly understood as they invoke both synergistic and antagonistic relationships [164].  
Indeed, Ras has been reported to suppress β -catenin levels but also to promote β -
catenin transcription [184, 185].  The net effect appears to be context dependent.  
However, in vivo studies have confirmed that defects in the two pathways can synergize 
to promote cancer [161].   
Here I show that Ras promotes the binding of NORE1A to β-TrCP1, the substrate 
recognition component of the SCF-β-TrCP ubiquitin ligase and this interaction promotes the 
degradation of β-catenin (Figure 25).  As I identified NORE1A and β- TrCP1 in a yeast 
two-hybrid interaction screen, this interaction is likely to be direct.  The interaction of 
NORE1A with β -TrCP1 explains how Ras can negatively regulate β -catenin and how 
such regulation may be defective in tumor cells that have suffered inactivation of 
NORE1A.  By using FTIs to inhibit the endogenous activated Ras in my NCI-H1299 cell 
system, I were able to show that Ras down-regulates endogenous β -catenin protein 
levels in the presence of NORE1A but enhances them in its absence.  Thus, the levels 
of NORE1A in a cell may play a major role in determining the net effect of Ras on β -
catenin.  However, it is not impossible that these experiments also impacted non-Ras 
farnesylated targets. So further experiments to examine the biological effects of the 
Ras/NORE1A/β-TrCP1 interaction may be warranted. 
At this point, the mechanism by which NORE1A specifically stimulates SCF-β-TrCP 
ubiquitin ligase activity via β -TrCP1 remains unclear.  In order for substrates to be 
recognized by β-TrCP, they first must be phosphorylated.  Therefore, I hypothesize 
NORE1A may potentially be acting as a scaffold for other substrate regulatory 
components, including GSK-3β, Axin, and APC.  Furthermore, in order for ubiquitin 
ligases to function properly, the E3 component requires a complex of several proteins 
















Figure 25.  Diagram of the Proposed Novel NORE1A/β-TrCP Signaling Module – 
Here I show my proposed Novel Ras/NORE1A/Wnt signaling pathway. I interpret my 
data to suggest that this Ras/NORE1A signaling pathway activates β -TrCP towards a 
subset of its substrates such as β -catenin but not IkB.  This results in differential 




Schmidt et al., 2014 




these E1 and E2 elements, specifically SCF (Skip/Cullin/F-Box) components, resulting in 
an enhanced stabilization of a functional ubiquitin ligase complex.  Lastly, perhaps 
NORE1A functions in recruiting, scaffolding, and stabilizing specific β-TrCP substrates 
for ubiquitination including β-catenin, Claspin, REST, or DEPTOR, explaining the 
observed altered substrate specificity of β-TrCP often found in cancer.   
β-TrCP1 can act as a tumor suppressor [174], as is expected since it can serve 
as a negative regulator of β -catenin, but has also been reported to exhibit oncogenic 
functions in some cellular environments [175, 176].  This may be due to its effects on 
substrates in addition to β -catenin.  These include a range of proteins involved in cell 
cycle regulation and transcriptional control such as IκB [190, 191], NFκB [192], GLI2 
[193, 194], REST [195, 196], ATF4 [197], CDC25A [198, 199], CDC25B [199], and 
Claspin [200, 201].  It seems likely that mechanisms exist to target β-TrCP to particular 
substrates under particular conditions.  NORE1A may be part of such a mechanism as it 
activates β-TrCP1 towards β-catenin but not towards IκB. As I found that the ability of β-
TrCP1 to suppress growth of tumor cells is heavily dependent upon the presence of 
NORE1A, it may be the NORE1A status of a cell that dictates whether or not β-TrCP1 is 
oncogenic or tumor suppressive.  It will be interesting to determine which other 
substrates NORE1A activates β-TrCP1 against.  
 NORE1A is not the first member of the RASSF family to be identified as binding 
to β -TrCP1.  A splice variant of the RASSF1A protein, RASSF1C, can also bind [202].  
However, unlike NORE1A, RASSF1C acts to somehow stabilize β-catenin protein levels 
and enhance β -catenin signaling.  Perhaps it acts by competing with NORE1A for 




 Another pathway that RASSF family members have been associated with is the 
Hippo pathway.  This pathway is a major signaling mechanism involved in controlling 
organ size and apoptosis [203].  The canonical Hippo signaling pathway involves a 
kinase cascade where MST kinases phosphorylate LATs kinases which then act on the 
transcriptional co-regulators YAP and TAZ [204].  RASSF proteins, such as NORE1A, 
can bind the MST/Hippo kinases [10]; nevertheless, NORE1A does not enhance their 
activity toward the Hippo pathway executors YAP and TAZ by MST/LATS 
phosphorylation [135].  However, in addition to β -catenin, β -TrCP1 also binds and 
regulates the stability of YAP and TAZ [205].  Interestingly, the Hippo pathway intersects 
with the Wnt pathway at many levels.  The first intersection discovered identified a point 
of β-catenin regulation where TAZ could interact with Dishevelled disrupting GSK-3β 
phosphorylation of β-catenin, effectively stabilizing Wnt signaling [206].  Additionally, the 
Hippo pathway has been shown to enhance transcription of Wnt target genes by 
upregulating the ability of β-catenin to transcribe target genes [207].   Finally, a recent 
study demonstrated that YAP and TAZ are required elements for recruitment of β-TrCP 
to the β-catenin destruction complex and are degraded together with β-catenin [208].  
Therefore, the interaction of NORE1A with β -TrCP1 may allow NORE1A to invoke 
powerful non-canonical Hippo pathway regulation outside of the MST1/2 kinases.  This 
may prove to be a potent additional mechanism where the RASSF family proteins 
contribute to growth and survival control. 
 Thus, I identify a function for NORE1A acting as a Ras activated control element 
for β-TrCP that stimulates the ubiquitin ligase complex towards specific targets.  These 
results may explain, mechanistically, many of the apparent contradictions in the 










NORE1A INTERACTS WITH GSK-3β ENHANCING  
β-CATENIN PHOSPHORYLATION   
 
4.1 - Introduction 
 
Signaling by the Wnt family of proteins is one of the core cellular mechanisms 
that coordinate cell proliferation, cell polarity, and tissue homeostasis [14, 209].  
Mutations in the Wnt pathway are often associated with human birth defects and cancer 
[203].  The most studied aspect of the Wnt signaling mechanism is centered on the 
regulation of the transcriptional co-activator, β -catenin, which controls key 
developmental genetic expression programs [209].  In normal tissue growth and 
development, the cell requires coordination between signal transduction pathways such 
as the Hippo and Wnt/β-catenin pathways.  In normal cells receiving Wnt signal, Wnt 
promotes growth and proliferation [210].  However, in cancer, Wnt signaling is typically 
corrupted into an Wnt signal independent “on” state as a result of one of several genetic 
mutations, most of which center around proteasomal regulation of β-catenin [210].  
In the canonical Wnt/β-catenin signaling pathway, β -catenin serves as both a 
nuclear transcriptional co-regulator and core component of adherens junctions [166].  
The cellular mechanism involved in the control of β-catenin is centered on the presence 




complex consisting of APC, Axin, and GSK-3β, phosphorylates β -catenin.  The 
phosphorylation is a required step for recognition and binding by β -TrCP, the E3 
component of the SCF-β-TrCP ubiquitin ligase complex.  SCF-β-TrCP mediated ubiquitination 
of β -catenin results in its rapid degradation by the 26S proteasome [211].  When Wnt 
ligand activates this pathway, the GSK-3β phosphorylation complex is disrupted by 
Disheveled family proteins allowing for unphosphorylated β -catenin levels to quickly 
increase in the cytoplasm and translocate to the nucleus [168]. Nuclear β -catenin 
functions as a coactivator for transcription factors of the TCF/LEF family, modulating 
genes involved in growth and survival [168].   While cells constitutively synthesize β -
catenin to maintain a ready response to incoming Wnt signaling, the very quick turnover 
rate of β -catenin maintains a proper signaling balance [173].  Dysfunction in the 
regulatory mechanism of β -catenin has been described in many human cancers and 
mutated forms of β -catenin which cannot be phosphorylated by GSK-3β are potently 
oncogenic [168].   
 In the previous chapter, I characterized a novel, direct interaction between 
NORE1A and β-TrCP, the E3 component of a SCF ubiquitin ligase complex [212].  This 
Ras mediated complex effectively regulated β-catenin protein stability and established a 
novel role for NORE1A in the regulation of oncoprotein stability [212].  Accordingly, loss 
of NORE1A expression resulted in an increase in steady state levels of β -catenin and 
resistance to β -TrCP mediated growth inhibitory effects [212].  Nonetheless, before β -
catenin can be recognized and ubiquitinated by β-TrCP, it first must be phosphorylated 
by GSK-3β.  NORE1A has no known enzymatic activity and appears to function in cells 
as a scaffolding protein [13, 130, 212, 213].  Perhaps a potential function of NORE1A in 
the regulation of β -catenin (Wnt pathway) works by scaffolding GSK-3β to β -TrCP 




NORE1A would remove a key negative Ras mediated regulatory element and may 
explain why Ras and Wnt are often found co-activated in many human cancers [214]. 
 To determine if NORE1A is determining factor governing the effects of Ras on 
Wnt signaling, a series of studies were undertaken.  Here I now show that NORE1A 
forms an endogenous complex with GSK-3β.  This novel protein/protein interaction 
between NORE1A and GSK-3β results in a coordinated and enhanced GSK-3β 
phosphorylation of β -catenin.  I also show that when cells were treated with LiCl2, a 
specific inhibitor of GSK-3β activity, NORE1A lost the ability to enhance β -catenin 
degradation.   Moreover, a triple point mutant of NORE1A that fails to bind GSK-3β is 
deficient in suppressing β -catenin.  The NORE1A/GSK-3β mechanism appears to 
operate independently of Ras signaling and more than likely has much broader 
implications with respect to cellular tumor suppression.  Furthermore, this novel 
interaction provides key insight into RASSF tumor suppression control via NORE1A.  
 
4.2 - Results 
 
NORE1A forms and endogenous complex with GSK-3β   
I previously published that NORE1A can negatively regulate β-catenin protein levels by 
interacting with the E3 ubiquitin ligase, β -TrCP [212].   However, NORE1A has been 
recently shown to interact with kinases involved in Hippo and p53 signaling [14, 133].  
Thus the potential exists for NORE1A to interact with kinases involved in β -catenin 
regulation.  While β-catenin is regulated by a dual-kinases system consisting of CK1 and 
GSK-3β, the latter actually marks β-catenin for recognition and ubiquitination by β-TrCP 




HEK293T cells were transfected with expression constructs expressing HA-GSK-3β and 
a GFP-NORE1A along with an activated H-Ras(12Val).  Cells were lysed 24 hours post-
transfection and immunoprecipitated against the GFP-epitope tag.  NORE1A was found 
in complex with GSK-3β and this interaction did not seem to be affected by the presence 
of Ras (Figure 26).  To determine if this result was physiological, MCF-10A cells were 
lysed and an antibody against GSK-3β was used to immunoprecipitate GSK-3β.  
NORE1A was again found in an endogenous complex (Figure 27). 
 
NORE1A enhances phosphorylation of β-catenin.   
Since NORE1A and GSK-3β were found in an endogenous complex, I next 
sought to determine if NORE1A enhances phosphorylation of β -catenin.  H1299 cells, 
null for NORE1A expression, were transfected with either an empty vector or pZIP-HA-
NORE1A.  Transformants were selected using G418 yielding a stable population that 
was +/- for NORE1A expression.  Using an antibody against specific GSK-3β 
phosphorylated residues of β -catenin (Ser33/37/Thr41), cell lysates from H1299 cells 
that were +/- for NORE1A were analyzed by Western blot to see if NORE1A enhances 
GSK-3β mediated phosphorylation of β -catenin.  In the lysates from cells expressing 
NORE1A, there was a substantial increase in phosphorylated β -catenin 
(Ser33/37/Thr41) when compared to lysates expressing empty pZIP-HA-vector (Figure 














Figure 26.  NORE1A Complexes with GSK-3β  - HEK-293T cells were transfected with 
expression constructs for NORE1A, GSK-3β, and a constitutively activated H-Ras 
(12Val).  NORE1A was immunoprecipitated using anti-GFP agarose beads and levels of 
bound GSK-3β was analyzed by Western blot.  The results of this experiment show that 

















Figure 27.  Endogenous Immunoprecipitation of NORE1A and GSK-3β  - Whole cell 
lysates were prepared from MCF-10A cells and the purified extracts were 
immunoprecipitated (IP) with anti-GSK-3β for 16 hours and then immunoblotted (IB) for 
NORE1A.  IgG incubated with MCF-10A lysate and Ig/GSK-3β antibody incubated with 
lysis buffer serve as the negative controls.  MCF-10A lysate serves as the positive 


















Figure 28.  NORE1A Enhances β-catenin Phosphorylation on GSK-3β  Target 
Residues - H1299 cells, null for NORE1A expression, were transfected with either pZIP 
vector or pZIP-HA-NORE1A.  Transformants were selected using G418 yielding a stable 
population that is either +/- for NORE1A expression.  Cells were lysed and analyzed on 
a Western blot for phosphorylated β-catenin.  In the cells expressing NORE1A, there is a 











Lithium Chloride prevents NORE1A mediated β-catenin degradation.   
To determine if NORE1A is using GSK-3β or another kinase to phosphorylate 
and drive β-catenin degradation, I chose Lithium Chloride to specifically inhibit GSK-3β 
phosphorylation activity [216].  HEK-293 cells were transfected with expression 
constructs expressing β-catenin paired with either an empty vector or HA-NORE1A.  As 
expected, in the presence of NORE1A, levels of β-catenin are difficult to detect (Figure 
29).  However, when LiCl2 is added to the cell media for 24 hours, NORE1A loses the 
ability to suppress β-catenin protein levels when analyzed by Western blot (Figure 29).  
NORE1A can bind several cellular kinases, including HIPK2 [14].  HIPK2 is known to be 
able to regulate β-catenin as well [217].  However, LiCl2 specifically inhibits GSK-3β and 
does not disrupt HIPK2 kinase activity [218].  Thus, this result helps confirm that 
NORE1A is in fact working through GSK-3β and not mediating β -catenin 
phosphorylation via other kinases like HIPK2. 
 
Disruption of the NORE1A/GSK-3β interaction suppresses the ability of NORE1A 
to downregulate β-catenin.   
To further support the Lithium Chloride data, I sought to develop a point mutant 
of NORE1A that disrupted its binding to GSK-3β.  Using fragment mapping and site 
directed mutagenesis, a triple point mutant of NORE1A was developed mutating the 92-
94 residues from Arg to Ala.  HEK-293T cells were transfected with expression 
constructs for GSK-3β paired with empty vector, NORE1A, and the triple point mutant 
(NORE1A 92-94A mutant).  24 hours post-transfection, the cells were lysed and the cell 
lysate was immunoprecipitated using GFP-conjugated agarose beads.  The assay was 
then analyzed on a Western blot where GSK-3β was found to complex strongly with 










Figure 29.  Inhibition of GSK-3β  Kinase Activity Blocks NORE1A’s Effects on β-
catenin - HEK-293 cells were transfected with expression constructs expressing 
NORE1A and β-catenin.  24 hours post-transfection, the cells were treated with LiCl2 for 
another 24 hours.  LiCl2 is known to be an effective inhibitor of GSK-3β kinase activity.  
In the cells treated with LiCl2 at a final concentration of 10mM, NORE1A mediated 
downregulation of β-catenin is impaired.  This result suggests that NORE1A is regulating 















Figure 30.  Development of NORE1A Point Mutant that Fails to Bind GSK-3β  - In 
order to further understand the cellular implications of the NORE1A/GSK-3β interaction, 
mutations were made in NORE1A focused on disrupting its interaction with GSK-3β.  
Deletion mutagenesis suggested that potential GSK-3β binding region rested in the 92-
94 amino acid residues of NORE1A.  These residues were mutated to Alanine residues 
via PCR mutagenesis.  Then HEK-293T cells were transfected with expression 
constructs for GSK-3β and either wild-type NORE1A or the mutant NORE1A (92-94A).  
Cells were lysed 24-hours post-transfection and immunoprecipitated.  Wild-type 
NORE1A was found in complex with GSK-3β.  However, the mutant NORE1A (92-94A) 









The mutant NORE1A was then employed to see if disruption of the interaction between 
NORE1A and GSK-3β affects the observed downregulation of β-catenin.  HEK-293 cells 
were transfected with expression constructs expressing either β -catenin and 
subsequently paired with an empty vector, wild type NORE1A, or the mutant NORE1A 
92-94A.  Results show the wild type NORE1A suppressed β-catenin protein levels, while 
the mutant NORE1A (92- 94A) was unable to suppress them (Figure 31).  This is in 
agreement with the LiCl2 experiment and again supports the idea that NORE1A is 
indeed coordinating GSK-3β to regulate β-catenin.      
 
4.3 - Discussion 
 
 The evolutionarily conserved Wnt signaling pathway is a vital signaling 
mechanism controlling a wide range of cellular processes including growth, 
development, tissue repair, and organogenesis [219].  In canonical Wnt signaling, Wnt 
ligands activate the pathway by binding to the Frizzled receptor [14].  Activation of this 
receptor stabilizes cellular levels of β-catenin and results in the formation of a 
transcriptional complex containing a DNA-binding factor known as lymphocyte enhancer 
factor (Lef), T-cell factor (Tcf) driving transcription of a set of growth and development 
genes [13].  However, a very intricate set of events is required before this complex can 
be stabilized and begin transcription.  Wnt signaling involves the inhibition of a 
constitutively active degradation mechanism that keeps cytosolic “signaling” pool of β -
catenin at low levels [13].  Disruption of this degradation complex allows β-catenin levels 
to quickly increase where it can then enter the nucleus to drive transcription of the 










Figure 31.  Disruption of NORE1A/GSK-3β  Impairs NORE1A Degradation of β-
catenin - HEK-293 cells were transfected with expression constructs expressing β -
catenin paired with empty vector, wild-type NORE1A, and the mutant of NORE1A that 
fails to bind GSK-3β (NORE1A92-94A).  In cells expressing β-catenin with empty vector, 
protein levels of β-catenin are high.  As expected, in the presence of wild-type NORE1A, 
levels of β-catenin are suppressed.  Intriguingly, when β-catenin was co-expressed with 
the 92-94A mutant, β -catenin was not degraded and appears to be stabilized to an 
extent suggesting that the 92-94A mutant may be acting as a dominant negative with 








catenin is rapidly degraded through ubiquitin mediated proteasomal degradation.  The 
kinases CKI and GSK-3β play central roles in controlling β -catenin levels [13].  Yet, 
studies show that cells require very strict coordination in regulating β -catenin protein 
levels to maintain homeostasis, and disruption of these mechanisms is often oncogenic 
[168].   
Glycogen synthase kinase 3 (GSK-3β) is a serine/threonine kinase that is an 
important component of numerous signaling pathways involved in the regulation of cell 
survival, protein synthesis, glycogen metabolism, cell mobility, and proliferation [220].  In 
addition to these functions, GSK-3β also negatively regulates many proto-oncogenic 
proteins and cell cycle regulators via the ubiquitin proteasome system [221].  When 
considering the broad range of oncogenic targets, it is easy to assume that GSK-3β 
functions to suppress tumorigenesis and indeed several studies support the view that 
GSK-3β functions as a tumor suppressor.  Oddly enough, unlike most other protein 
kinases, GSK-3β is constitutively active.  Thus, other factors that affect its proper 
function, including the presence or absence of scaffolding molecules, must exist to 
regulate target acquisition and are likely key in determining the oncogenic potential of a 
cell.   
 Since GSK-3β negatively regulates many proto-oncogenic proteins and cell cycle 
regulators, a tumor suppressive role makes perfect sense [221].  However, some studies 
suggest that GSK-3β may actually promote tumorigenesis and cancer development as 
GSK-3β over expression has been observed in human ovarian, colon, and pancreatic 
cancers [222].  Hence, it remains controversial whether GSK-3β is a tumor suppressor 
or tumor promoter.  Therefore, the role GSK-3β plays in cancer is likely complex and 
may be dependent on specific cellular circumstances or perhaps the presence or 




GSK-3β regulates many diverse substrates and signaling pathways, and the 
mechanisms that determine its tumor suppressive function are indeed complicated.  One 
of the better-characterized roles of GSK-3β on tumor suppression is centered on its 
control of β -catenin, the terminal executor of the Wnt signaling pathway.  
Phosphorylation of β -catenin by GSK-3β targets it for ubiquitination by the substrate 
recognition protein β-TrCP and subsequent proteasomal degradation.  Activation of Wnt 
signaling disrupts GSK-3β mediated phosphorylation of β-catenin allowing cellular levels 
of β -catenin to increase.  As β-catenin levels climb, the protein moves to the nucleus 
where it co-activates transcription of genes of the TCF/LEF gene group.    
Over 15 years of study has revealed multiple, subtle links between the Ras and 
Wnt/β-catenin pathways.  The links are complex, occur at multiple levels, and remain 
poorly understood as they invoke both synergistic and antagonistic relationships [164].  
Ras has been reported to suppress β -catenin levels but it has also been reported to 
promote β-catenin mediated gene transcription [184, 185].  The net effect appears to be 
situationally dependent.  While the antagonistic effects are likely not tumorigenic, the 
synergistic effects likely are tumorigenic and in vivo studies confirmed that defects in the 
two pathways can promote cancer [161].  Data shown thus far supports my original 
hypothesis names NORE1A has the potential to be the link that determines whether Ras 
can activate or suppress Wnt.  
 In the previous chapter, I showed how Ras signaling enhances the binding of 
NORE1A to β-TrCP, enhancing ubiquitination of specific substrates regulated by the β-
TrCP ubiquitin ligase [212].  β -TrCP is the E3 substrate recognition component for the 
SCF-β-TrCP ubiquitin ligase complex and is known to be the major ubiquitin ligase involved 
in the regulation of β-catenin protein levels.  I now present evidence that NORE1A has 




interaction between NORE1A and GSK-3β and demonstrate that NORE1A can activate 
the kinase activity of GSK-3β towards a specific substrate of the Wnt pathway, β -
catenin.  NORE1A appears to be working exclusively through the GSK-3β kinase as a 
specific GSK-3β kinase inhibitor, LiCl2, blocks the ability of NORE1A to suppress β -
catenin protein levels.  Furthermore, a mutant of NORE1A that fails to bind GSK-3β is 
deficient in properly regulating β -catenin protein levels.  Taken together, these results 
suggest that NORE1A is working to control Wnt signaling by coordinating both 
phosphorylation and ubiquitination of β-catenin (Figure 32).  NORE1A and GSK-3β play 
an essential role in the Ras mediated regulation of Wnt/β-catenin signaling and loss of 
NORE1A shifts the relationship between Ras and Wnt from antagonistic to protagonistic 



























Figure 32.  Enhanced Diagram of the Proposed NORE1A/GSK-3β /β-TrCP Signaling 
Complex - This schematic, depicting a novel NORE1A mediated protein regulatory 
complex, demonstrates how I hypothesize NORE1A to function as a scaffolding 
molecule in this protein regulatory complex.  NORE1A binds and enhances both GSK-3β 
and β-TrCP activity on the specific substrate, β-catenin.  Perhaps the reason for this lies 
in the potential for NORE1A to be scaffolding the individual elements of this complex 
together.  Bringing the kinase and ubiquitin ligase in close proximity may determine the 












NORE1A SPECIFICIALLY REGULATES TAZ INDEPENDENTLY OF HIPPO BY 
SCAFFOLDING GSK-3β TO β-TRCP 
 
5.1 - Introduction 
 
The Hippo signaling pathway is an evolutionarily conserved signaling mechanism 
that regulates organ size by controlling the cell cycle, regulating cell proliferation, and 
activating apoptosis [223, 224].  In tissue growth and development, the cell requires 
strict coordination of signal transduction pathways.  The Hippo pathway was first 
believed to be important in human cancers when observations made in Drosophila 
melanogaster tissues containing Hippo mutations are transformed [225].  More recent 
experiments using mice and studies involving the screening of human cancer genomes 
have validated this belief by identifying that mutations in Hippo signaling are indeed 
oncogenic [226, 227].  Despite recent progress, full understanding of the Hippo pathway 
remains incomplete [228].  While the conserved canonical Hippo signaling pathway has 
been established, potentially important variations on this cascade await characterization 
in mammals [228].  Furthermore, additional levels of Hippo regulation potentially exist as 
it is likely that several upstream inputs remain to be discovered and defined [228].  
 The Hippo pathway consists of a signaling cascade of proteins that cooperate in 




in a small core component of the canonical Hippo pathway.  These components include 
the protein kinases LATS1/2 and MST1/2, which function as members of a kinase 
cascade [229].  These kinases work to phosphorylate and degrade the terminal 
elements of the Hippo pathway, the transcriptional co-activators YAP and TAZ [230, 
231]. YAP and TAZ bind to and co-activate transcription factors including TEAD and β-
catenin to activate transcription of genes required for cell survival and proliferation [207, 
232, 233].  In recent years, the Hippo signaling pathway has gained increasing attention 
as mutations in the upstream regulatory components leading to the ineffective regulation 
of YAP/TAZ have been identified in human cancers [234].  Both YAP [235, 236] and TAZ 
[237, 238] exhibit oncogenic properties and elevated TAZ expression can be found in a 
wide variety of aggressive cancers [239].  
 The Hippo pathway cross-talks with several other signaling pathways such as 
Notch, Wnt, Sonic hedgehog (Shh) [240].  However, there is another pathway that can 
regulate Hippo and has some of the most powerful impacts on cellular oncogenesis, and 
that pathway is the Ras signaling pathway.  This establishes an interesting paradigm 
where you have two molecular pathways, one that causes cancer and one that protects 
against it, signaling through each other.  Ras has been shown to stimulate both 
oncogenic transformation and apoptosis through activation of a variety of effectors [241].  
While the pro-transformation elements of Ras signaling are fairly well characterized, the 
pro-apoptotic mechanisms that protect the cell from hyper-active Ras stimulation are far 
less understood.  A key breakthrough occurred when it was discovered that Ras 
modulates pro-apoptotic MST signaling activity via the RASSF family of proteins, 
canonically activating the Hippo pathway [241]. 
 RASSF1A, a member of the RASSF family, was shown to bind MST and activate 




MST kinase activity as well as binding to its substrate, LATS [242, 243].  Activation of 
the LATS kinase in turn leads to the phosphorylation of YAP [241].  LATS has been 
shown to phosphorylate YAP on multiple residues, each having different regulatory 
functions [244]; however, one of the key residues in apoptotic signaling involves 
phosphorylation of YAP on S127, which leads to its cytosolic sequestration and 
subsequent degradation [244].   
 Several other members of the RASSF family also have the potential bind MST 
using a special conserved domain termed the SARAH (Salvador/RASSF/Hippo) 
domain[133].  Thus, it was not surprising when NORE1A (RASSF5) was found to bind 
the MST kinases [10].  Initially, it was believed that NORE1A, much like RASSF1A, 
activated the MST kinases [10].  However, upon further study, this initial finding has 
become somewhat controversial [135].  The aforementioned study showed that while 
NORE1A indeed binds, MST, there was no evidence found linking NORE1A to the 
activation of its kinase activity [135].  Furthermore, a mutant of NORE1A that fails to 
complex with MST still powerfully functions as a tumor suppressor [129].  Therefore, in 
contrast to RASSF1A, NORE1A likely fulfills its function as a tumor suppressor 
independently of canonical Hippo signaling.  
 In canonical Hippo signaling, YAP and TAZ are usually considered to be co-
regulated.  When the upstream kinase module of MST1/2 and LATS1/2 is activated, 
YAP and TAZ are equally phosphorylated leading to their inhibition of transcriptional 
activity through 14-3-3 mediated cytoplasmic sequestration and proteasomal 
degradation [225].  However, the regulation of the two terminal Hippo pathway executors 
is not identical.  While YAP and TAZ are co-regulated canonically by Hippo activated 
LATS-dependent phosphorylation, it was later discovered that TAZ has multiple 




different mechanisms of regulation [205].  While LATS phosphorylation of TAZ at S89 
results in cytoplasmic sequestration, phosphorylation by the same kinase at S311 results 
in recognition and ubiquitination by the SCF-β-TrCP ubiquitin ligase complex leading to its 
degradation in the 26S proteasome [205].  Furthermore, TAZ contains another N-
terminal phosphodegron that is unique and not found in YAP [245].  This phosphodegron 
at S58/62 is recognized by the GSK-3β protein kinase, activating an additional 
recognition site for β -TrCP ubiquitination [18].  While the same SCF E3 component is 
involved in recognition of both the C-terminal LATS phosphodegron and the N-terminal 
GSK-3β phosphodegron, these mechanisms are distinctly different and either one is 
found to be sufficient to induce TAZ degradation [18]. 
 In Chapter III, I identified and characterized a direct interaction between 
NORE1A and β-TrCP, the E3 component of a SCF ubiquitin ligase complex [212].  This 
Ras mediated complex effectively regulated β -catenin protein stability and provided 
insight on how NORE1A functions as an effective scaffolding protein [212].  Accordingly, 
loss of NORE1A expression resulted in an increase in steady state levels of β -catenin 
and resistance to β-TrCP mediated growth inhibitory effects [212].  During my studies, I 
noticed that NORE1A expression appeared to specifically suppress the stability of TAZ 
rather than YAP.  As TAZ, and not YAP, is specifically regulated by a GSK-3β 
phosphodegron/SCF-β-TrCP ubiquitination process, I hypothesized that NORE1A might 
act as a Ras regulated scaffold to modulate the action of GSK-3β and SCF-β-TrCP on TAZ, 
as well as β-catenin. 
 Here I now show NORE1A regulates TAZ outside of canonical Hippo signaling.  
My data shows that NORE1A is found in an endogenous complex with GSK-3β and acts 
as a Ras regulated scaffold for GSK-3β and β-TrCP.  This allows NORE1A to promote 




pathway.  Moreover, this property is an essential component of NORE1A tumor 
suppressing activity, as a point mutant of NORE1A that cannot interact with GSK-3β is 
defective for suppression of TAZ, and defective for the ability to promote senescence 
[14]. 
 Thus I identify a novel mechanism by which Ras can control TAZ levels 
independently of the canonical Hippo pathway.  Moreover, as the role of GSK-3β in 
cancer development is now known to be extensive [246], the identification of a 
Ras/NORE1A/GSK-3β signaling pathway may reveal a novel function of Ras.  
 
5.2 - Results 
 
NORE1A Differentially Regulates Hippo pathway endpoints YAP and TAZ 
NORE1A was originally thought to regulate cellular apoptosis by binding and 
activating the MST1/2 kinases, resulting in an induction of Hippo apoptotic signaling [10].  
However, another study would go on to show that NORE1A does not activate MST1/2 
kinase cascade [135].  In response to these opposing reports, I sought to determine if 
NORE1A had any effect on the stability of YAP and TAZ, thereby modulating Hippo 
pathway signaling.  To investigate this, HEK-293 cells were transfected with mammalian 
expression plasmids expressing YAP or TAZ paired with either NORE1A or an empty 
vector control.  Here I observed YAP stability was not affected by the presence of 
NORE1A (Figure 33).  However, TAZ protein levels were powerfully suppressed in the 
presence of NORE1A demonstrating that NORE1A differentially regulates YAP and TAZ 












Figure 33.  NORE1A Differentially Regulates YAP and TAZ -  NORE1A differentially 
regulates YAP and TAZ.  To determine whether NORE1A regulated YAP and TAZ in 
similar manners or with similar specificity, I took HEK293 cells and transfected them with 
expression constructs expressing YAP or TAZ paired with an empty vector or a construct 
expressing NORE1A.  24 hours post-transfection, the cells were lysed and the total 
levels of YAP and TAZ were examined by Western blot.  NORE1A strongly 









Knockdown of NORE1A expression leads to enhanced steady state levels of TAZ 
To confirm the result from figure 33 where NORE1A suppresses TAZ protein 
levels, I tested whether knocking down NORE1A had the reverse effect on endogenous 
steady state TAZ.  To achieve this, HEK293 cells were transfected with two different 
shRNA constructs against NORE1A [14, 212].  48-hours post-transfection, the cells were 
lysed and analyzed on a Western blot for levels of endogenous TAZ.  In the cells where 
NORE1A was suppressed, there was a substantial increase in steady state levels of 
TAZ (Figure 34). 
 
Lithium Chloride treatment blocks NORE1A mediated down-regulation of TAZ 
In addition to GSK-3β, NORE1A has been reported to interact with the MST1/2 
kinases [133].  These kinases can also mark TAZ for degradation.  So I sought to 
determine whether NORE1A was working through GSK-3β by using a specific GSK-3β 
inhibitor, LiCl2 [218, 247].  HEK-293 cells were transfected with a construct expressing 
TAZ paired with either an empty vector or a construct expressing NORE1A.  24 hours 
post-transfection, the transfected cells were split and treated with either LiCl2 or water, 
which served as the carrier solution.  24 hours after treatment with the GSK-3β inhibitor, 
the cells were lysed and the cell lysates were examined by Western blot.  As expected, 
in the absence of LiCl2, NORE1A effectively suppresses TAZ protein levels.  However, in 
the presence of LiCl2, the ability of NORE1A to suppress TAZ was markedly reduced 
suggesting that NORE1A is indeed working via GSK-3β to suppress TAZ protein levels 














Figure 34.  Knockdown of NORE1A Results in Increased Steady-State TAZ Levels - 
To confirm the over-expression data where NORE1A suppressed TAZ protein levels, I 
sought to determine whether knockdown of NORE1A would impair the cell’s ability to 
properly regulate the growth and survival regulator, TAZ.  HEK293 cells were transfected 
with shRNA constructs against NORE1A and lysed 48-hours post-transfection, and the 
cell lysates were examined by Western blot.  In the cells where NORE1A was knocked 


















Figure 35.  Lithium Chloride Impairs the Ability of NORE1A to Regulate TAZ - HEK-
293 cells were transfected with expression constructs expressing NORE1A and TAZ.  24 
hours post-transfection, the cells were treated with LiCl2 at a final concentration of 10mM 
for another 16 hours.  LiCl2 is known to be an effective inhibitor of GSK-3β kinase 
activity.  In the cells treated with LiCl2, NORE1A mediated downregulation of TAZ is 
impeded.  This results suggests that NORE1A is regulating TAZ protein levels in 










Disruption of the NORE1A/GSK-3β interaction suppresses the ability of NORE1A 
to down-regulate TAZ independently of Hippo (MST) 
To confirm the Lithium Chloride data suggesting that NORE1A is regulating TAZ 
independently of canonical Hippo signaling (MST), I went back and employed the mutant 
of NORE1A that lost the ability to bind GSK-3β (NORE1A92-94A mutant). HEK-293T 
cells were transfected with expression constructs for GSK-3β paired with empty vector, 
NORE1A, and the triple point mutant, NORE1A92-94A mutant.  GSK-3β was found to 
complex strongly with NORE1A; however, GSK-3β failed to complex with the mutant 
NORE1A (Figure 30).  This mutant does not, however, disrupt binding to MST, allowing 
for us to specifically isolate NORE1A/GSK-3β functions (Figure 36) [14].   
Moving further, in addition to being regulated by GSK-3β, TAZ is canonically 
regulated by Hippo signaling where the cellular levels of TAZ protein are suppressed by 
activation the MST/LATS kinase cascade.  Like other RASSF family members, NORE1A 
has the ability to bind the MST1/2 kinases [133].  However, this may not result in their 
activation [135]. Thus, I sought to more conclusively determine whether NORE1A is 
working through MST1/2 kinases (Hippo) or through the GSK-3β kinase, or perhaps both 
MST1/2 and GSK-3β to regulate TAZ.  To eliminate Hippo components, I used a 
NORE1A deletion mutant lacking the SARAH motif which cannot bind MST kinases [9]. 
To confirm that the deletion of the SARAH motif disrupted MST1/2 binding to NORE1A, 
HEK-293T cells were transfected with expression constructs expressing Myc-MST along 
with an empty vector, GFP-NORE1A, or the truncation mutant GFP-NORE1AΔSARAH.  
Cells were lysed 24 hours post-transfection and immunoprecipitated against the GFP 
epitope tag.  MST was found in a complex with NORE1A, however, when NORE1A 
loses the SARAH domain, binding to MST is ablated (Figure 37).  After it was 













Figure 36.  Wild-Type NORE1A and the 92-94A Mutant Complex with MST - TAZ 
can be regulated by both GSK-3β and MST kinases.  Figure 30 showed that the 
NORE1A92-94A mutant failed to bind GSK-3β and I needed to know whether this 
mutation also disrupted the ability of NORE1A to bind MST.  HEK-293T cells were 
transfected with expression constructs expressing NORE1A, the 92-94A mutant, and 
MST.  Whole cell lysates were immunoprecipitated by GFP-agarose beads and the 


















Figure 37. Removal of the NORE1A-SARAH Domain Disrupts NORE1A/MST 
Binding - To isolate the effects of the NORE1A/MST interaction, I sought to develop a 
mutant of NORE1A that fails to complex with MST.  NORE1A is known to associate with 
MST via the SARAH (Salvador/RASSF/Hippo) domain.  I removed this domain from the 
protein and performed a co-immunoprecipitation to confirm that removal of the SARAH 
domain disrupted the ability of NORE1A and MST to bind.  HEK-293T cells were 
transfected with expression constructs expressing NORE1A, the ΔSARAH, and MST1.  
Cells were immunoprecipitated after 24 hours and the IP was analyzed by Western blot.  
I confirmed that removal of the SARAH domain disrupted the ability of NORE1A to form 




binding to GSK-3β.  HEK-293T cells were transfected with expression constructs 
expressing HA-GSK-3β paired with an empty vector, GFP-NORE1A, and GFP-
NORE1AΔSARAH.  The cells were lysed 24 hours post-transfection and 
immunoprecipitated.  While the removal of the SARAH domain disrupted NORE1A 
binding to MST, it did not affect its binding to GSK-3β (Figure 38).   
These mutants of NORE1A were then employed in an experimental system 
allowing investigation of the relative importance of the interactions between NORE1A, 
MST, and GSK-3β to down-regulate TAZ. HEK-293 cells were transfected with 
expression constructs expressing HA-TAZ paired with a GFP-vector, GFP-NORE1A, 
GFP-NORE1A92-94A, or GFP-NORE1AΔSARAH.  The cells were lysed 24 hours post-
transfection and levels of TAZ were analyzed by Western blot.  Agreeing with previous 
results, the wild-type NORE1A strongly suppressed TAZ protein levels and the mutant of 
NORE1A that failed to complex with GSK-3β also failed to down-regulate TAZ protein 
levels (Figure 39).  Furthermore, the mutant of NORE1A that retains binding to GSK-3β 
and not MST still effectively regulates TAZ protein levels.  Thus, NORE1A can regulate 
TAZ outside of canonical Hippo signaling operating through GSK-3β instead of MST1/2 
(Figure 39).      
 
NORE1A suppresses TAZ transcriptional co-activation via GSK-3β 
Data presented thus far shows that NORE1A powerfully suppresses TAZ protein 
stability.  Thus, I sought to determine whether this suppression also resulted in a 
suppression of TAZ mediated TEAD promoter activity.  To answer this, I performed a 
series of luciferase assays using a TEAD-promoter reporter construct (TEAD-Luc).  
HEK-293 cells were transfected with expression constructs expressing HA-TAZ and the 









Figure 38.  NORE1A-ΔSARAH Mutant Retains Binding with GSK-3β  - HEK-293T 
cells were transfected with expression constructs expressing wild-type NORE1A and the 
truncation mutant lacking the SARAH domain with GSK-3β.  While the SARAH-less 
NORE1A failed to bind MST (Figure 37), data shown here shows that it still complexes 





















Figure 39.  NORE1A Regulates TAZ Independently of Hippo (MST) Via GSK-3β  - 
Now that I have developed two mutants of NORE1A that each bind only one of the 
kinases that regulate TAZ, I sought to see if I could identify whether NORE1A was 
regulating TAZ via GSK-3β, MST, or both.  HEK293 cells were transfected with an 
expression construct expressing TAZ paired with wild-type NORE1A, the 92-94A mutant 
(fails to bind GSK-3β), or the ΔSARAH (fails to bind MST).  I found that wild-type 
NORE1A and the mutant that does not complex with MST both strongly suppressed TAZ 
protein levels.  However, the mutant of NORE1A that fails to complex with GSK-3β also 
failed to suppress TAZ.  Taken together, this supports my hypothesis that NORE1A 






NORE1AΔSARAH.  Wild-type NORE1A suppressed TAZ mediated TEAD-promoter 
activation (Figure 40).  Additionally, the triple point mutant of NORE1A (92-94A) that 
failed to bind GSK-3β also was unable to suppress TAZ activation of the TEAD promoter 
(Figure 40).  Yet, the mutant of NORE1A (ΔSARAH) that fails to bind MST, but still 
binds GSK-3β, was still able to suppress TAZ mediated TEAD activation (Figure 40).  
These observations correlate with my protein stability observations and show that 
NORE1A mediated TAZ suppression indeed affects transcription of TEAD. 
 
NORE1A coordinates with β-TrCP to control TAZ protein levels 
I recently reported that NORE1A can form a direct, Ras regulated complex with 
the E3 ubiquitin ligase, β-TrCP [212].  TAZ is known to be ubiquitinated by β-TrCP, and 
it is entirely plausible that NORE1A may also be regulating TAZ by coordinating GSK-3β 
with β -TrCP.  To test this hypothesis, HEK-293 cells were transfected with expression 
constructs expressing TAZ along with an empty vector, NORE1A, and β - TrCP.  TAZ 
protein levels were suppressed in the presence of NORE1A and β-TrCP, and the effect 
was amplified when both NORE1A and β -TrCP were co-expressed with TAZ (Figure 
41).  However, when a dominant negative β -TrCP (ΔFBOX) was transfected into this 
experimental system, it disrupted the ability of NORE1A to effectively down-regulate TAZ 
(Figure 41), showing that NORE1A is also using β-TrCP to regulate TAZ. 
 
NORE1A scaffolds β-TrCP and GSK-3β to form a protein regulatory complex 
I have shown that NORE1A can complex with key elements of an ubiquitin ligase 
mechanism that control phosphorylation and subsequent ubiquitination of substrates.  





Figure 40.  NORE1A Suppresses TAZ Mediated TEAD Promoter Activity - To 
investigate whether NORE1A mediated TAZ protein suppression (Figure 39) also 
resulted in a suppression of TAZ mediated TEAD transcriptional co-activation, HEK293 
cells were transfected with a TEAD luciferase reporter construct along with an 
expression construct expressing TAZ.  I then paired this system with either wild-type 
NORE1A, the 92-94A mutant, or the truncation mutant lacking the SARAH domain.  
Echoing the results from the protein stability experiment, wild type NORE1A (p=0.001) 
and the mutant that fails to bind MST (ΔSARAH) (p=0.001) still both strongly suppressed 
TAZ mediated transcriptional activity.  The mutant of NORE1A that failed to bind GSK-3β 
(92-94A) also failed to suppress TAZ (p=0.25) mediated transcriptional activity further 
supporting my hypothesis that NORE1A is regulating TAZ independently of Hippo 











Figure 41.  NORE1A Cooperates with β-TrCP to Regulate TAZ Protein Levels - 
Phosphorylation of TAZ results in its recognition and subsequent ubiquitination by the E3 
ubiquitin ligase, β-TrCP.  I previously published that NORE1A can bind and regulate β-
TrCP, and I sought to see if NORE1A was also regulating TAZ via β -TrCP.  HEK293 
cells were transfected with expression constructs expressing TAZ along with NORE1A, 
NORE1A paired with β-TrCP, and NORE1A paired with a catalytically inactivate β-TrCP 
(ΔFBOX).  NORE1A suppression of TAZ was enhanced in the presence of β -TrCP.  
Intriguingly, the effect was impaired when a dominant negative β-TrCP (ΔFBOX) was co-
expressed with NORE1A.  Taken together, this supports that NORE1A is also 





effective scaffolding element.  Perhaps NORE1A regulates different cellular protein 
substrates by scaffolding GSK-3β to β-TrCP and enhancing its mechanistic productivity.  
To investigate this, HEK-293T cells were transfected with a HA-GSK-3β along with GFP-
Vector or GFP-β-TrCP with and without Flag-NORE1A.  Cells were lysed 24 hours post-
transfection and the cell lysates were immunoprecipitated by the GFP-tag and analyzed 
by Western blot.  I found GSK-3β in a barely detectable complex with β-TrCP, however, 
the addition of NORE1A strongly stabilized the complex (Figure 42).  Thus, this data 
suggests that NORE1A indeed works as a scaffolding protein stabilizing the GSK-3β and 
β-TrCP into a protein complex.  This observation helps explain how NORE1A functions 
in the regulation of TAZ as well as helps support my hypothesis from Chapter IV where 
NORE1A scaffolds GSK-3β to β-TrCP to Regulate β-catenin.   
 
NORE1A cooperates with GSK-3β  to induce cellular senescence 
In primary mammalian cells, expression of oncogenes, such as activated Ras, 
induces premature senescence rather than transformation [248].  Ras (Oncogene) 
induced senescence can be bypassed by a number of different genetic events including 
inactivation of the p53/p21/p19ARF pathway, inactivation of the Rb family of proteins, 
and aberrations in p53, PML, SIR2, KLF4, and YAP/TAZ [248, 249].  Recent research 
has now identified GSK-3β as a key player in the activation of cellular senescence [248, 
250, 251].  These reports demonstrate that loss GSK-3β expression is a key factor that 
determines whether a cell transforms or becomes senescent in the presence of 
constitutively active Ras [248].  Exactly how GSK-3β functions in senescence is not 
exactly clear and likely occurs on multiple levels including regulation of β-catenin, p53, 










Figure 42.  NORE1A Scaffolds GSK-3β  to β-TrCP - NORE1A may be functioning as a 
scaffolding molecule stabilizing a protein degradation complex comprised of a priming 
kinase and associated ubiquitin ligase.  Reports have shown that TAZ protein levels are 
regulated by GSK-3β and β -TrCP.  Perhaps NORE1A functions as a scaffolding 
molecule and stabilizes these proteins in a complex.  To test this, HEK-293T cells were 
transfected with expression constructs for GSK-3β, β -TrCP, and NORE1A.  24 hours 
post-transfection, cells were lysed and immunoprecipitated.  GSK-3β and β -TrCP were 
detected weakly in a complex.  However, in the presence of NORE1A, the association 





powerful senescence effector that functions through both p53 and possibly other 
pathways including Rb and p16 [14].  Now that I have shown that NORE1A binds and 
scaffolds GSK-3β, and considering that both NORE1A and GSK-3β are implicated in 
activating Ras (oncogene) induced senescence (OIS), I sought to determine whether 
NORE1A functions through GSK-3β to shift cells into a senescent phenotype.  To 
achieve this, I took A549 cells and transfected them with either an empty vector or an 
expression construct expressing a GFP-tagged NORE1A.  6-hours post-transfection the 
cells were then treated with LiCl2 or water, the carrier solution, at a final concentration 
of10mM for 72-hours.  The cells were then processed using a β-gal senescence kit.  The 
number of positive blue cells were counted and quantified.  Results show that NORE1A 
strongly induced a senescent phenotype in the A549 cells and this effect was 
suppressed by the LiCl2 suggesting that NORE1A is using GSK-3β in part as a 
senescence effector (Figure 43, 44).   
 
NORE1A Induced Senescence is Suppressed By Overexpression of TAZ 
While GSK-3β is known to be able to activate senescence via several cellular 
targets including p53 and β-catenin[250, 251], recent research has now identified that 
loss of TEAD transcriptional activity can also be a factor to induce cellular senescence 
[249].  Accordingly, the potential exists that NORE1A’s regulation of TAZ via GSK-3β 
functions as another arm of NORE1A senescence.  Since I have shown that NORE1A 
indeed induces senescence by GSK-3β, I were then curious whether this was due to its 
regulation of TAZ or if NORE1A and GSK-3β were cooperating to induce senescence via 






Figure 43.  Lithium Chloride Blocks the Ability of NORE1A to Induce Senescence - 
NORE1A is a powerful inducer of senescence.  While p53 is one of the better-
characterized pathways in which NORE1A functions in senescence, I have data that 
now suggests that NORE1A can also induce senescence through alterations in the 
Hippo pathway endpoint, TAZ.  Loss of TEAD promoter activity has been reported to 
shift cells into senescence [249]. So, I sought to determine whether suppression of GSK-
3β impairs the ability of NORE1A to induce cellular senescence.  A549 cells were 
transfected with expression constructs expressing an empty vector or NORE1A.  6-hours 
post-transfection, the cells were treated with LiCl2 at a final concentration of 10mM for 
72 hours.  The cells were then processed for β-gal activity using a senescence detection 
kit.  The cells were then counted and the results quantified.  As expected, NORE1A 
strongly shifted cells into senescence (p=0.05).  This effect was impaired in the presence 













Figure 44.  Representative Pictures from the NORE1A Senescence Assay - 
Representative photographs taken of A549 cells in the senescence assay described in 
Figure 10.  Positive cells are easily seen with blue color, most prevalent in the A549 cells 









To test this hypothesis, I surmised that excessive over-expression of TAZ would 
over-come the ability of NORE1A to regulate TAZ and induce senescence, thus 
reversing or suppressing the ability of NORE1A to induce senescence.  A549 cells were 
transfected with an empty, and expression construct for NORE1A, and then an 
expression construct for NORE1A along with an expression construct for TAZ 
transfected in a 5 times the amount used in previous experiments.  Here I found that 
NORE1A on its own increased the level of cellular senescence from roughly 12% 
background level to roughly 42% (Figure 45).  However, when levels of TAZ were 
elevated to where NORE1A could no longer successfully regulated them, the ability of 
NORE1A to induce senescence was suppressed and only about 20% of the cells were 
found to be β-gal positive (Figure 45).  Thus, this experiment defines a novel NORE1A 
senescence arm and NORE1A fulfills its role as a senescence effector by the 
downregulation of TAZ, suppressing its ability to co-activate TEAD promoter genes. 
 
5.3 - Discussion 
 
The Hippo signaling pathway performs key roles in both organ size and 
tumorigenesis; however, components of the Hippo pathway are deregulated in various 
human cancers.  In canonical Hippo signaling, the core mechanism employs a kinase 
cascade consisting of the MST1/2 and LATS1/2 kinases to phosphorylate the major 
functional output components YAP and TAZ, marking them for degradation [204, 253].   
YAP and TAZ are transcriptional co-activators that exert powerful survival signals 

















Figure 45.  Identification of a Novel NORE1A Senescence Arm – NORE1A 
cooperates with GSK-3β to drive senescence by suppressing TAZ mediated co-
activation of TEAD.  A549 cells were transfected with expression constructs expressing 
an empty vector, NORE1A, and NORE1A along with excessive levels of TAZ.  NORE1A 
again powerfully induces senescence (p=0.05).  However, this induction is over-powered 
when levels of TAZ rise above the ability of NORE1A to properly regulate it.  Thus, 
NORE1A is able to induce senescence by the downregulation of TEAD genes co-





specific regulation to maintain cellular homeostasis.  YAP and TAZ each share 
approximately 50% sequence homology, yet they contain differences including lack of an 
N-terminal proline-rich domain and a SH3 binding motif [204].  This would suggest YAP 
and TAZ potentially have both conserved and non-conserved modes of regulation [204].  
YAP/TAZ are rarely found mutated in different cancers, yet improper regulation of these 
proteins is commonly observed in human tumors [254, 255].  Conversely, suppression of 
YAP and TAZ protein levels results in inhibition of cellular proliferation and a shift to 
apoptosis and senescence [256].  Taken together, this suggests that its not mutations in 
YAP and TAZ specifically, but dysfunction in their regulatory mechanisms that can drive 
oncogenesis. 
Although YAP and TAZ are co-regulated by Hippo signaling, TAZ differs from 
YAP in possessing a unique, Hippo independent phospho-degron [18].  This phospho-
degron is recognized by the GSK-3β kinase and phosphorylation of TAZ by GSK-3β 
promotes its degradation via the β-TrCP degradation complex.  Thus, TAZ and YAP can 
be both co- and differentially regulated. 
 One of the inputs that can regulate the Hippo pathway is Ras [232, 257].  
Although Ras is a potent oncoprotein and is implicated in the development of the 
majority of human tumors [258, 259], activated Ras is paradoxically capable of 
stimulating apoptosis and senescence [7, 14].  The Hippo pathway is one of the best 
characterized of these Ras death effector pathways.  Ras is connected to Hippo 
pathway by its effector RASSF1A.  RASSF1A is a member of the RASSF family of 
proteins and directly binds MST kinases [260].  The interaction of Ras with RASSF1A 
promotes the activation of the MST kinases and therefore Hippo pathway activation, 
leading to down-regulation of YAP.   Many tumors exhibit loss of RASSF1A expression 




 NORE1A, like RASSF1A, is a RASSF family member that serves as a direct, pro-
apoptotic Ras effector [10, 11]. NORE1A suppresses tumor cell growth, is frequently 
inactivated in human tumors, and genetic inactivation of NORE1A is implicated in a 
hereditary cancer syndrome [15, 126, 187].  Therefore, NORE1A is likely to serve as an 
important human tumor suppressor and its loss results in a marked cellular oncogenic 
shift.  Like RASSF1A, NORE1A also binds the MST kinases directly, and thus has the 
potential to connect Ras to the Hippo pathway [10].  However, deletion mutants of 
NORE1A that cannot interact with MST kinases retain the ability to inhibit cell growth 
and suppress the tumorigenic phenotype [129].  Moreover, a thorough biochemical 
analysis did not support an obvious role for NORE1A in MST kinase activation [135].  
Thus, unknown tumor suppressor pathways independent of the canonical Hippo 
signaling pathway must be modulated by NORE1A.  
 We recently showed that NORE1 forms a direct, endogenous complex with β -
TrCP [212].  β -TrCP is the E3 substrate recognition component for the SCF-β-TrCP 
ubiquitin ligase complex, and is a key element in regulation of both Wnt and Hippo.  
During my experiments examining the role of NORE1A in Hippo signaling, I noticed that 
NORE1A appeared much more active towards TAZ than YAP.  Bearing in mind it has 
been shown that NORE1A does not seem to activate MST kinases, even though it binds 
them [135], I wondered if NORE1A might be activating a TAZ specific/β-TrCP non-
canonical degradative pathway. 
 My experiments have shown that NORE1A does indeed preferentially suppress 
cellular TAZ protein levels via β -TrCP.  However, I also found that NORE1A not only 
interacts with β -TrCP, but also forms an endogenous complex with the kinase 




 GSK-3β is a serine/threonine kinase that is an important component of diverse 
signaling pathways involved in the regulation of cell survival, protein synthesis, glycogen 
metabolism, cell mobility, and proliferation [220]. It appears to function to suppress 
tumorigenesis, yet the roles in which GSK-3β operates as a tumor suppressor are not 
fully characterized [221].  One of the better-studied roles of GSK-3β in tumor 
suppression is centered on its control of β -catenin, the terminal executor of the Wnt 
signaling pathway.  Phosphorylation of β-catenin by GSK-3β targets it for ubiquitination 
by the substrate recognition protein β -TrCP resulting in its subsequent proteasomal 
degradation.  
Unlike many other protein kinases in the cell, GSK-3β has constitutively active 
kinase activity [262].  Thus, control of GSK-3β function may rely on targeting proteins 
that control it’s coupling to the appropriate substrate.  NORE1A may serve as one of 
these targeting proteins, for when I used a specific GSK-3β inhibitor; I blocked the ability 
of NORE1A to promote TAZ degradation.  Thus I reveal a new function for NORE1A as 
a scaffolding molecule for GSK-3β.  This links NORE1A to the potential control of a 
broad range of targets some of which include β-catenin, Snail, Smad1, Smad3, BCL-3, 
p21, HIF-1α, and Cyclin D1 [263].  However, although I found that the interaction of 
NORE1A with β -TrCP was Ras dependent [212], its interaction with GSK-3β was not.  
Therefore, NORE1A may have Ras dependent and Ras independent effects on GSK-3β 
activity.  
One of the most interesting aspects of this study is the revelation that NORE1A 
differentially regulates Hippo pathway endpoints.  Much of the research on RASSF 
family proteins attributed their tumor suppressive capabilities to their binding of the MST 
kinases, and subsequent activation of canonical Hippo signaling as a conserved 




Hippo has revealed that their relationship is much more complicated [129, 133].  While it 
is well demonstrated that RASSF1A can regulate YAP stability by enhancing MST/LATS 
phosphorylation on S127, I have never observed NORE1A to do the same, despite the 
fact that I, and others, have shown that NORE1A complexes with MST.  Thus, NORE1A 
must be performing other tasks with MST; however these tasks are not involved in the 
regulation of Hippo signaling and at this point remain largely uncharacterized.   
NORE1A still remains connected into the Hippo signaling pathway, but unlike its 
close family relative, RASSF1A, NORE1A functions non-canonically and specifically 
regulates the Hippo pathway endpoint, TAZ.  Initially, I was unsure what the implications 
of the specific regulation of one of the two Hippo pathway endpoints were on the cell 
until I found a report showing that varying degrees of alterations in TEAD transcriptional 
output alter whether the pathway is apoptotic or senescent [249].  Explained further, the 
full suppression of YAP and TAZ mediated TEAD activation by canonical Hippo signaling 
is indeed apoptotic, yet partial suppression of TEAD by specific regulation of YAP or 
TAZ by non-canonical mechanisms induces a senescent phenotype preferentially over 
the activation of apoptosis.  This provides some of the first explanations why RASSF1A 
appears to be an apoptotic effector while NORE1A appears to be a senescence effector.   
Thus, I identify a novel role for NORE1A in scaffolding the protein kinase GSK-3β 
to ubiquitin ligase β-TrCP.  NORE1A is key in the stabilization of this complex and loss 
of NORE1A impairs the ability of GSK-3β and β-TrCP to properly regulate substrates 
such as TAZ.  Furthermore, I now know that NORE1A can complex with several other 
kinases involved in β-TrCP phosphodegron process including HIPK2 [14], Aurora 
Kinase, and PLK-1 (unpublished observations).  Thus, this highlights a new potential role 
for NORE1A in protein regulation by functioning mechanistically as a scaffolding various 











 This work identifies a completely new and unanticipated signaling pathway for 
the Ras oncogene.  It reveals that NORE1A forms a direct, physiological, Ras regulated 
complex with the ubiquitin ligase substrate recognition protein β-TrCP.  This allows Ras 
to use NORE1A as an effector to regulate the stability of multiple proteins playing key 
roles in growth, transformation, and death.  Mechanistically, it shows NORE1A acts as a 
scaffolding protein facilitating complex formation between GSK-3β and β-TrCP to 
enhance proteasomal regulation of β-catenin and TAZ, which are the active end points 
of the Wnt and Hippo pathways respectively (Figure 46).       
 These results provide a mechanistic explanation for some of the contradictory 
reports previously published in the literature describing the relationship between Ras 
and Wnt.  In the presence of NORE1A Ras is a negative regulator of β-catenin, but in its 
absence is a positive regulator.  Moreover, these results also explain discrepancies in 
the reported role of NORE1A in the regulation of the Hippo pathway.  They show that 
NORE1A does not activate the canonical Hippo pathway, but exhibits a potent and 
specific non-canonical regulation of the TAZ half the YAP/TAZ transcriptional co-
activator endpoints of Hippo signaling.  This allows us to explain why NORE1A is far 




















Figure 46.  Diagram of the Novel Ras/NORE1A/GSK-3β /β-TrCP Signaling Pathway 
– This schematic shows the previously accepted model for NORE1A mediated tumor 
suppression (A) along with my Novel Ras/NORE1A signaling pathway allowing for the 
coordinate control of the Wnt (β-catenin) and Hippo (TAZ) signaling pathways (B).  My 
results show that NORE1A scaffolds GSK-3β to β-TrCP qualitatively and quantitatively 
enhancing their phosphorylation and ubiquitination of oncogenic substrates.  Moreover, I 
identify a novel NORE1A senescence arm where NORE1A splits the Hippo, specifically 
regulating TAZ and not YAP, resulting in the partial suppression of TEAD transcriptional 
activity and the activation of cellular senescence. 
Adapted	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   permission	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Experiments showing that NORE1A has no effect on the β-TrCP target IκB 
confirmed that the pathway is specific to a sub-set of the broad range of β-TrCP target 
proteins.  This may help explain why β-TrCP has been reported to exhibit both 
oncogenic and tumor suppressive functions in different systems as levels of NORE1A 
present may dictate its balance of forces.     
 Future studies should be centered on finding other kinases that cooperate with β-
TrCP in protein regulation and investigating whether NORE1A also scaffolds them into a 
single kinase/ubiquitin ligase complex.  Key kinases worth investigating are PLK-1 
(involved in Claspin regulation), HIPK2 (involved in regulation of numerous proteins), 
and RSK1 (involved in DEPTOR regulation).  Additionally, other β-TrCP substrates 
should be examined to see if NORE1A is involved in their regulation as well.  One that 
immediately comes to mind is the MDM2 ubiquitin ligase.  This ubiquitin ligase controls 
p53 stability and since NORE1A and p53 cooperate to induce senescence, a Ras 
regulated mechanism where NORE1A cooperates to negatively regulate MDM2 is an 
intriguing possibility and warrants examination.  Such an interaction might allow co-
ordinate suppression of TAZ and activation of p53 to achieve senescence. 
Finally, this project may also have ramifications for personalized medicine 
focused on Ras tumors, as Ras tumors lacking NORE1A expression may be quite 
different in the utilization of the Wnt and Hippo pathways compared to those retaining 
the expression of NORE1A.  Therefore, patients receiving treatments for a Rasopathy 
should have the NORE1A status of the tumor determined to see if they require 
coordinate therapies targeting Wnt and Hippo as well the oncogenic form of Ras.  
Coordinate therapies may enhance the effectiveness of targeting mutated Ras and may 
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